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The human sweat gland is differentiated into eccrine and apocrine sweat glands. The 
major function of eccrine sweat gland is thermoregulation during hot environments and 
rigorous exercise.  Silver stained 2D gel by Marshal et al (1984) detected approximately 
300 protein spots from healthy human sweat samples.  The exact composition of proteins 
present in healthy human sweat still remains unclear. Studies in the elucidation of the sweat 
proteome will pave the way for identification and to understand the functions of sweat 
proteins.  
 
This study describes an integrated approach of eccrine sweat proteome profiling using 
a 2DE MALDI-TOF/TOF MS and 2D-LC-MS/MS that has helped identify 98 unique 
proteins. By combining the two most widely used protein profiling techniques (2DE and 
2D-LC-MS/MS), this study has achieved the most comprehensive characterization of the 
human sweat proteome till date.  This study provides valuable information regarding the 
protein components of healthy human sweat which will pave the way for establishing the 
functions of sweat proteins and elucidate their role as a part of the innate defense system. 
Some of the proteins identified in sweat can be also used as biomarkers for diagnostic 
purposes. 
 
The antimicrobial proteins deposited on to the skin via sweat act as an important part 
of the first line of defense against invading pathogens which prevent the pathogens from 
colonizing the skin and establishing an infection. This study attempted to identify the 
antimicrobial proteins present in healthy human sweat apart from those that have been 
previously reported.  This lead to the identification of three novel antibacterial proteins in 
ix 
 
sweat, Superoxide dismutase 1(SOD1), Cystatin A and Lactoferrin with promising 
antibacterial activity against Streptococcus pyogenes, Escherichia coli and Staphylococcus 
epidermidis respectively.  
 
We are exposed to a vast array of pathogens present in the environment, which 
includes not just bacteria but also viruses. Herpes simplex virus-1 (HSV-1) is one such virus 
which causes diseases on the face and skin. The impact of HSV-1 on human health globally 
is enormous due to its high incidence, association with immuno-compromised patients, and 
ability to cause recurrent disease. This study reports the presence of Cystatin A and 
Lactoferrin in sweat with antiviral activity against HSV-1. Studies into the mechanism of 
action of these proteins revealed that they inhibit important stages of HSV-1 life cycle.  
 
This study also reports the identification of two epidermal wound repair proteins 
present in sweat -SOD1 and Calgranulin B. In vitro and in vivo studies have quantitatively 
established the wound repair function of these proteins. This study to the best of our 
knowledge for the first time presents the quantitative analysis of the wound repair function 
of these proteins. 
 
In conclusion, this study has successfully lead to the identification of the protein 
composition of healthy human sweat. This study has also identified sweat proteins with 
antibacterial, antiviral and epidermal wound repair functions with potential applications as 
pharmaceutical leads. Hence, proving the presence of immune effectors in sweat and thus 
paving the way for the establishment of our understanding of sweat as a part of innate 
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C H APT E R 1: INT R O DU C T I O N 
1.1 H uman sweat glands 
1.1.1 Types of sweat glands  
 
The skin is the largest human organ. Human skin comprises of almost 10% of 
the body mass of an average person and it covers an average area of 1.7m2. Its major 
function is to serve as a protective barrier and to shield the body from undesirable 
pathogens from invading the skin and gaining entry into the body. The next major 
function of skin is maintaining homeostasis and regulation of body temperature by the 
secretion of sweat.  The sweat gland is one of the major components of the skin 
epidermis. A human body consists of 3-4 x106 sweat glands distributed throughout the 
surface of the body (Yousuke et al., 1995).   
 
Human body consists of two types of sweat glands 1) Eccrine sweat glands and 
2) Apocrine sweat glands. The eccrine sweat glands form one of the major cutaneous 
appendages (Sato et al., 1989). The eccrine sweat glands are present throughout the 
surface of the skin, densities ranging from about 60 per cm2 on the thigh to 350 per 
cm2 on the forehead (Quinton et al., 1983). The main function of eccrine sweat glands 
is thermoregulation i.e. regulation of body temperature during hot environments and 
during physical exercise. Failure to regulate body temperature during such conditions 
can lead to heat stroke and/or hyperthermia.   
 
The apocrine sweat glands are large sweat glands. The apocrine glands are 




such as axillae, nipples and ano-genital regions. The apocrine sweat glands open to 
hair follicles. 
 
1.1.2 Functions of Sweat . 
 
The most important function of sweat is thermoregulation. Humans are 
normally known to produce sweat in response to heat, physical stress such as exercise 
and emotional stress. Sweat is mostly composed of water which has high specific heat 
capacity. Body heat is transferred from the skin to sweat. As sweat evaporates, it  
transfers the heat away and in doing so cools the body temperature.  
 
 1.1.3 Human sweat composition 
 
Sweat mainly consists of water, sodium, chloride, potassium, urea and lactate. 
Eccrine sweat can be considered as a dilute electrolyte solution. An exact composition 
of sweat is difficult to state but the normal range of solutes in a healthy human sweat 
can be determined for a few of the solutes present in sweat. The major solute present 
in sweat is NaCl. Sodium values range from 30 to 240 mg/ 100 ml, potassium from 9 
to 62 mg/100 ml, magnesium from 0.04 to 4.5 mg/100 ml, and phosphorus from 9 to 
43 ʅg/100 ml of sweat (Frank et al., 1962). Apart from salts sweat also consists of 
organic compounds such as urea.   
 
The early pioneering work by Page et al, revealed that human sweat contains 
protein components apart from urea, salts and water. The major proteins of normal 
KXPDQ VZHDW DUH DOEXPLQ Į-globulin, and gamma-globulin (Page et al., 1967). 
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Further to this study was the detection of around 300 protein spots in Silver stained 2D 
electrophoresis gel by Marshal et al., (1984).  This study was one of the pioneering 
studies in determining and establishing the fact that human sweat consists of 
numerous proteins apart from salts and urea. 
 
A few decades later, studies reported the presence of an antimicrobial peptide 
(AMP) in sweat such as Dermcidin (DCD) (Birgit et al., 2001) and Psoriasin (Glaser 
et al., 2005). Hence it was suggested that sweat contains AMP to regulate the normal 
human skin flora and thus preventing the skin from numerous pathogens that are 
present in the surrounding environment. 
    
Later reports indicated the presence of an anti-allergy protein in sweat. Group 
1 allergens Der p 1 and Der f 1 belong to papain-like cysteine protease family, mostly 
found in mite faecal pellets. Research studies have shown that the cysteine protease 
activity of Der p 1 stimulates airway epithelial cells causing the release of cytokines 
and chemokines thus promoting the establishment of an allergic state. Cystatin A -a 
cysteine protease inhibitor present in sweat inhibited the proteolyitc activities of Der p 
1 and Der f 1 (Kato et al., 2005).   
 
1.1.4 Innate immunity-first line of host defense. 
 
The human immune system is composed of innate (the focus of this study) and 
adaptive immunity. Innate immunity is the first to be mobilized immediately after an 
infection and hence is called the first line of defense against the invading pathogen. 
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The innate immunity is triggered by the following- anatomic barrier (e.g. skin), 
phagocytic cells, complement pathways, inflammation and fever.  
 
Human skin forms one of the most important parts of innate immune defense 
system as it prevents the entry of foreign particles or pathogens into the system. This 
prevention is achieved by the presence of cells that are present in the skin such as 
keratinocytes, sebocytes, eccrine glands which produce AMP. AMP are known to be 
deposited on the skin surface via sweat is Dermcidin, Psoriasin, Cathelicidin etc 
(Schauber et al., 2008). These AMPs protect the human system from the constant 
microbial threat posed by the environment. The importance of these AMPs is further 
emphasized by the fact that decreased expression of these AMPs has been shown to be 
involved in the pathogenesis of cutaneous disease such as atopic dermatitis, psoriasis 
and rosaceous.  
 
1.1.5 Aims of this project 
 
As mentioned previously, literature has shown that sweat is composed of 
water, salts and proteins such as immunoglobulins, orosomucoids and most 
interestingly a few antimicrobial peptides. But the characterization of the protein 
composition of the healthy human sweat as determined by the silver stained 2D gel 
(Marshal et al., 1984) is still unknown. Studies into determining the exact identity of 
the protein composition of healthy human sweat will not just aid in re-defining the 
composition of sweat but also open new avenues in comprehending the functions of 
these sweat proteins. Thus setting the aims of this project as to: 
1) Identify the main components of the human sweat proteome. 
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2) Characterize some of the major protein components with respect to their 
potential innate immune function. 
 
In a quest to identify the major protein components present in healthy human 
sweat, and further establish few of the candidate sweat proteins as a part of the innate 
immune defense system, experimental procedures were designed and optimised. 






C H APT E R 2: IDE N T I F I C A T I O N O F H E A L T H Y H U M A N 
SW E A T PR O T E O M E . 
2.1 Introduction 
2.1.1 Proteomics  
  
Proteomics is defined as study of the protein complement in a given cell, 
tissue or organism. The study of protein profile of an organism is vital because the 
proteins are important for the structure and function of living systems. By studying 
and analysing the patterns of protein content and how the profile of proteins changes 
during development, disease conditions, we in turn understand the systems at cellular 
level.  
 
2.1.2 Study of human body fluids using proteomics approach 
  
Proteomics is envisaged to be a promising channel for biomedical research. 
The most suitable sample for a proteomics study appears to be body fluids due to 
factors including cost effectiveness, easy sample handling and processing and most 
importantly low invasive procedures used to obtain the body fluids. There has been 
growing interest in the use of proteomics for body fluids study to understand the 
normal physiology and the pathophysiology of diseases and also identification of 
novel biomarkers. 
 
 A number of proteomics tools are routinely used in human body fluid study. 
Most of these tools are a combination of high resolution protein separation and high 
sensitivity detection techniques. 
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Till date, numerous human body fluids have been studied with respect to their 
protein composition- serum (Pieper et al., 2003), tear (!"#$% &% et al., 2004) , urine 
(Pieper et al., 2004),  saliva ( Hu et al., 2005) , biliary proteins (Zhou H  et al., 2005), 
cerebrospinal fluid (Roch et al., 2008).  The proteomics platform used by most of 
these studies to database the respective proteome was liquid chromatography/mass 
spectrometry and two-dimensional gel electrophoresis-mass spectrometry.  Typically, 
the proteomics study involves the separation of proteins using a 2D gel and then 
visualising it by staining. The protein spots of interest are excised and then trypsin 
digested and the peptides thus obtained are analysed by MALDI-MS to measure their 
molecular masses.  An alternative approach is to directly trypsin digest the protein 
mixture followed by sorting of these peptides by one or more chromatographic 
techniques. The MS then analyses these peptides and computer matches them to 
proteins from which these peptides were derived (LC-MS/MS).  
  
Though human sweat proteins were analysed by two-dimensional gel 
electrophoresis (Marshall et al., 1984), which showed the presence of around 300 
proteins, the identity of these proteins is still unknown. Isolated studies have shown 
the presence of a few AMPs, immunoglobulins, glycoproteins and protease inhibitors 
in sweat, but the comprehensive profile of the sweat proteome is yet to be catalogued. 
 
 
2.1.3 Objectives of this study 
  
  
As mentioned previously literature studies have shown that healthy human 
sweat consists of a few proteins, which is contradictory to what was shown in the 
silver stained 2D gel by Marshall (1984). Hence a more thorough investigation of the 
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human sweat protein composition is required. Studies directed towards such global 
analysis will help understand the function of sweat and sweat proteins in particular 
apart from thermoregulation. Thus the main objective of this study is to characterize 
the healthy human sweat proteome.  
 
As mentioned in the previous section, numerous research studies are currently 
exploring the protein composition of body fluids using proteomics technology.  This 
study uses two of the most widely used and complimentary proteomics platforms-2DE 
followed by MALDI TOF/TOF analysis and 2D-LC-MS/MS analysis for 
identification of the proteins present in sweat.  
 
2.2 M ater ials and M ethods 
 
To elucidate the protein profile of healthy human sweat and to determine the 
identity of proteins present in the same it was decided to collect sweat from healthy 
individuals. Further, it was decided to use two of the most widely used and high 
resolution techniques, 2DE followed by MALDI-TOF/TOF and 2D-LC-MS/MS to 
study the sweat proteome and identify the protein profile of human sweat. The 2DE 
western blotting helped to further confirm and validate the identity of the proteins 
 
2.2.1 Sweat collection technique  
 
The study has been approved by the Institutional Review Board of National 
University of Singapore (07-023). Crude eccrine sweat was collected from five 
healthy male volunteers subjected to vigorous exercise after rinsing themselves in 
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water. The sweat dripping from the back, hands, palms and legs of the volunteers were 
allowed to drip into clean collection tubes. Care was taken to ensure least 
contamination by skin keratins by avoiding scraping the collection tube on the skin. 
The collected sweat was pooled and stored at -200 C until further processing. 
 
2.2.2 Separation and purification of sweat proteins 
 
The crude sweat proteins were freed from salts and other non-protein materials 
by dialyzing the sweat using dialysis membrane with a molecular weight cut-off of 3.5 
kDa (Pierce, USA), against distilled water for 72hrs.The distilled water was changed 
every 24 hours. The dialysis was carried out at 40C while being stirred. The dialyzed 
sweat proteins were further concentrated by lyophilization till a powdery white 
substance was obtained. The lyophilized sweat fraction was stored at -200 C till further 
use. 
 
2.2.3 2-Dimentional SDS-PA G E 
 
The lyophilized sweat sample was solubilised in a solubilising buffer 
containing: 2% SDS, 40mM Tris base and 60mM DTT (US Biological). The solution 
was then heated for 5min at 950C and vortexed to dissolve the proteins completely. To 
obtain a satisfactory 2DE protein map it is important to ensure that the sample is free 
from traces of salts and other interfering substances. Since sweat is known to contain a 
high concentration of salts and urea. The removal of salts is important to prevent the 
amperage sore during focusing. 2D clean up kit (GE Healthcare) was used to free the 
sample from salts and other interfering substances. The final pellet obtained after 
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using the 2D cleanup kit was re-suspended in destreak re-hydration solution (GE 
Healthcare) containing 2% ampholytes. The suspended sample with a protein 
concentration of 100µg was then loaded on to IEF strip pH range 4-7 (GE Healthcare). 
The first dimension (1D) was carried in a PROTEAN® IEF Cell isoelectro-focussing 
unit (Bio-rad) at 200C with maximum 50µA per strip and the following settings: 
rehydrating the strips with the sample for 16hrs and then 250V for 15 min, slow 
voltage increase to 8000V for 1hr followed by rapid voltage increase to 8000V and 
remaining at 8000V till the desired total Vhr 40K was reached.  In the second 
dimension the focused strip was reduced and alkylated using equilibration buffer using 
DTT (US Biological) and iodoacetamide (Sigma-Aldrich, St Louis, MO, USA). The 
reduced and alkylated peptides in the strip were separated in the second dimension 
(2D) by using 15% SDS-PAGE.  
 
2.2.4 2D Gel staining and imaging 
 
The separated sweat protein was detected by using silver staining technique. 
The gel was fixed in fixative solution (50% methanol + 10% Acetic acid) for 1 hour at 
room temperature. It was later sensitized with 0.8M sodium thiosulphate and washed 
twice with distilled water for 1min. Silver Nitrate reagent (0.2% Silver nitrate + 0.02% 
formaldehyde in distilled water) was added to the gel and incubated for 30 min on a 
shaker. The gels were washed twice with distilled water for 1 min and developed 
using Developing reagent (3% Na2CO3 and 0.05% formaldehyde). Once the desirable 
staining was achieved, the development was stopped using a stopping solution (0.5% 




2.2.5 In-gel digestion and peptide ext raction  
 
The separated sweat protein spots were excised and placed in C18 ZipPlate 
(Millipore) wells. The gel pieces were then washed with 25mM ammonium 
bicarbonate (ABC) / 5% acetonitrile (ACN) for 30 min. After washing, the wells were 
completely drained with vacuum and washed with 25mM ABC / 50% ACN for 30 
min followed by vacuum drain. 200µl of 100% ACN was then added to each well 
containing gel pieces and incubated for 10 min, after which each of the wells were 
completely drained to remove the ACN.  15µl of freshly prepared trypsin solution 
(final conc.:11ng/µl in 25mM ABC buffer) was then added to each well and the 
ZipPlate was incubated for 3 hr at 370C. Each digested peptide sample was extracted 
with 130µl of 0.2 % TFA and desalted. 20µl of Elution Solution (0.1 % TFA, 50 % 
ACN) was used to elute the peptides from the reverse-phase resin and the samples 
were dried at room temperature with a SpeedVac.  
 
2.2.6 Protein identification using M A L DI-T O F/T O F mass spect rometer 
 
Dried extract was re-dissolved in 1µl of matrix solution [5 mg/ml of D-cyano-
4-hydroxycinnamic acid (CHCA) in 0.1 % TFA, 50 % ACN] and spotted onto a 
MALDI target plate. The peptide samples were analyzed in reflector mode by a 4700 
Proteomics Analyzer MALDI-TOF/TOF mass spectrometer (Applied Biosystems, 
Framingham, MA, USA) as described previously (Bi et al., MCP 2006). The MS and 
MS/MS data were submitted to MASCOT search engine version 2.1 (Matrix Science 
Ltd., London, UK) for protein identification using IPI human database (Version 3.34; 
67,756 entries).  The maximum number of missed cleavage for trypsin was set at 1.  
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Modifications for search included carbamidomethylation of cysteine (fixed 
modification), methionine oxidation and N-terminal acetylation (variable 
modifications).  Precursor tolerance was set to 150 ppm and MS/MS tolerance was set 
to 0.4 Da. 
 
2.2.7 2 -Dimensional L iquid Chromatography -MS/MS (2D-L C-MS/MS) 
 
The sweat samples collected were dialyzed and lyophilized as mentioned 
above. The lyophilized fraction was re-dissolved in 50µl 50mM Tris buffer, pH 8.5. 
The suspended fraction was then centrifuged at 14,000 rpm for 5 min and the 
supernatant obtained was collected.  5µl of 100 mM TCEP was added to the 
supernatant and the sample was boiled at 1000C for 10 min. 20µl of 0.1 g/ml IAA was 
added and the sample was incubated at 370C for 2 hr. The sample was then trypsin 
digested overnight at 370C. The digested samples were desalted using Sep-Pak C18 
columns (Waters,). Once desalted the sample was freeze dried overnight and dissolved 
in minimum volumes of Buffer A (98% H2O + 2% ACN +0.05%TFA) and freeze 
dried further.  The dried peptide mixture was re-dissolved with 30 µl of Buffer A and 
separated by an Ultimate 2D-LC system (Dionex-LC Packings, Sunnyvale, CA) and 
collected onto MALDI target plates, as described previously (Li et al, MCP 2007).  
The MS and MS/MS data were collected with the 4700 Proteomics Analyzer MALDI-
TOF/TOF mass spectrometer as mentioned above.  Two LC-MS runs were performed 
with sweat samples collected from the same group of people at two different dates.  
Modifications for search included carbamidomethylation of cysteine (fixed 
modification), methionine oxidation and N-terminal acetylation (variable 
modifications).In order to achieve high confidence in protein identification, a Mascot 
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search of the MS data against a randomized database generated with the IPI human 
database Version 3.34 (generated using a Pearl script downloaded from 
http://www.matrixscience.com/help/decoy_help.html) was also performed.  The false 
positive rate (FPR) was calculated as follows: 
       Number of peptides/proteins identified in the randomized database 
FPR (%) =                             u  100 
          Number of peptides/proteins identified in the normal database 
 
For proteins with two or more peptide matches, 5% FPR as the cut-off 
threshold at the peptide level was used.  The FPR at the protein level was 0 as none of 
the sequences of the randomized database could have more than one peptide matches.  
For proteins with single peptide matches, we used a more stringent cut-off threshold at 
the peptide level. Only the peptides with the MOWSE scores greater than the top-
scored peptide in the randomized database were considered positive identifications.   
 
2.2.8 Western Blot Study  
 
In an attempt to validate the identity of the proteins, Western Blots were done 
using mouse monoclonal antibodies. Sweat from healthy volunteers was collected and 
pooled and was processed as indicated before and an SDS-PAGE gel was run after 
IEF. The proteins separated on the gel were electro-transferred onto a nitrocellulose 
membrane (GE Healthcare) by the process of electro-blot transfer (25V overnight at 
40C). The membrane was later washed with PBS and blocked with 4% non fat milk. 
Each of the membranes was incubated with specific monoclonal antibodies. The 
following primary antibodies were used: Psoriasin (US biological Inc, USA), Cystatin 
A ((Sigma-Aldrich, St Louis, MO, USA), Zinc Alpha glycoprotein (BD Transduction 
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Laboratories, USA), Cathepsin D (BD Transduction Laboratories, USA), Caspase-14 
(BD Pharmingen, USA), IgG (US Biological, USA) Calgranulin B (Biodesign, USA), 
Keratin 10 (Lab Vision, USA), Cytokeratin 2 (Abcam, UK), Cytokeratin 9 (BD 
Pharmingen, USA), SOD1 (BD Pharmingen, USA) and Lactoferrin (Abcam, UK). 
The secondary antibody used was rabbit anti-mouse secondary antibody conjugated to 
horseradish peroxidase (BD Pharmingen, USA) at a 1:2000 dilution. The blots were 
developed using enhanced chemiluminescence system (ECL; Amersham Pharmacia, 
USA). 
 
2.3 Results and Discussion 
 
2.3.1 2D proteome of healthy human sweat 
 
Approximately 200 spots were observed on the silver stained 2D gel (Fig 2.1). 
Each of the spots was excised, processed and identified by MALDI-TOF/TOF MS 
(Fig 2.2 and Table2.1). Many of the excised spots identified were shown to be 






F ig 2.1 Silver stained 2D gel of healthy human sweat proteins. Proteins (100µg ) 
obtained from pooled human sweat were separated on a pH 4±7 IPG strip in the first 
dimension and by 15% acrylamide SDS-PAGE in the second dimension. The resulting 
gel was silver stained. 
 
 
It is known that the outer skin is made up mostly of different types of keratins, 
with types and isoforms depending on the differentiation and proliferation state of the 
skin. The 2D proteome of sweat also showed different types of keratin spots spreading 
across the higher molecular weight region of the gel. Analysis of the excised spots 
revealed the presence of numerous isoforms of keratin 1, Cytokeratin 9, Cytokeratin 2 
keratin 10, keratin 5 (Fig 2.2) and many more as summarized in Table 2.1. The 
proteome profile of sweat has revealed the presence of a number of previously 
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unknown distinct proteins. Most of the protein spots were distributed in the high 
molecular weight region i.e. around 50kDa-150kDa and in the range of 10-20kDa. 
 
 
The zinc- alpha-2-glycoprotein (ZAG), detected at around 37kDa (Fig 2.2) was 
found to be the most abundant protein in the 2D proteome of sweat after keratin 1. 
Another protein that was detected in the same range as ZAG was the protease inhibitor 
like SerpinB6, a serine protease inhibitor (Fig 2.2). 
 
The proteins detected in the 10kDa -20kDa region (Fig2.2) mostly included the 
S100 family of proteins such as Psoriasin (also called S100A7) and Calgranulin A 
(S100A8) and Calgranulin B (S100A9). Proteins such as Prolactin induced protein and 







      F ig 2.2 Silver stained 2D gel of healthy human sweat proteins and identification of proteins by M A L DI-T O F/T O F MS. 
Each of the spots obtained on the silver stained 2DE gel was excised, in-gel trypsin digested and identified by MALDI TOF/TOF mass 
spectrometry. 
1:IgG, 2: Keratin, type II cytoskeletal 1, 3: Keratin, type II cytoskeletal 2 epidermal, 4: Keratin, type I  cytoskeletal 9, 5: 
Cathepsin D, 6: Serine(or cysteine) protease inhibitor, 7: Keratin, type I cytoskeletal 10, 8: Keratin, type II cytoskeletal 
6A, 9: Keratin, type II cytoskeletal 6C, 10: Keratin, type II cytoskeletal 5, 11: Serpin B3, 12: Keratin, type I cytoskeletal 
16, 13: TGM3 , 14: Zinc alpha-2-glycoprotein, 15: Serpin B6, 16:CREG1 , 17: SCCA1, 18:Prolactin induced protein, 




While a total of approximately 200 spots were excised from the silver stained 
2D gel of sweat and analyzed by MALDI±TOF/TOF MS, most of the proteins 
identified were found to be isoforms of the same protein e.g. ZAG, Cystatin A, 
Keratins etc. (Fig 2.2).  Thus 23 unique proteins were identified using the MALDI-
TOF/TOF MS platform, among these 23 proteins most of them were detected as 
numerous isoforms on the silver stained 2D gel as well as in the MALDI-TOF/TOF 
MS analysis. 
 
2.3.2 Identification of sweat proteins by 2D -L C- MS/MS 
 
Table 2.1 summarizes the proteins that were detected in the 2D-LC-MS/MS 
analysis. The 2D-LC MS/MS analysis revealed many other proteins that were not 
detected in the 2D- MALDI TOF/TOF analysis. The possible reasons for the higher 
number of  proteins detected in the 2D-LC-MS-MS platform as compared to the 2DE 
could be because of the higher sensitivity of 2D-LC-MS-MS and also that the chances 
of loss of sample is higher in 2DE as the entire 2D profile depends on the absorbance 
of the protein sample by the IEF strip.   98 unique proteins that were identified to be 
present in healthy human sweat, 75 of them were identified by 2D-LC-MS/MS 
approach; these include proteins like Lactoferrin, Calmodulin-like protein 5, Caspase-
14 precursor, etc.  Some proteins like S100A9 Protein, S100A7, Cathepsin D, ZAG 
etc. were identified by both the approaches. Fig 2.3 provides a quantitative 







F ig 2.3 Venn diagram showing number of sweat proteins identified by 2D 
M A L DI T O F/T O F MS and/or 2D-L C-MS/MS 
 
 
2.3.3 Gene Ontology 
 
Functional analysis of the 98 identified proteins according to Gene Ontology 
(Fig 2.4) reveals that 17 % of the proteins identified in human sweat have enzymatic 
function comprising of proteins like Cathepsin, Caspase-14, and SOD1 etc.  16 % of 
the human sweat proteome is composed of proteins with binding properties, and 14 % 
are part of the structural constituents which mainly included the various types of 
Keratins. The sweat proteome also showed the presence of a few calcium binding 
proteins such as S100 family of proteins and Calmodulin-like protein. 5% of the  


















F ig 2.4 Functional classes of proteins identified from human sweat protein 
according to Gene Ontology. 
 
2.3.4 Validation of Sweat proteins by Western Blot 
 
In an effort to further confirm and validate the proteins identified by 2D 
MALDI TOF/TOF and 2D-LC-MS/MS, we performed 2D and 1D Western blotS. Fig  
2.5 show the results of Western blots for some of the proteins identified by both 
methods.  The Western blot results further confirmed and validated the identity of the 
proteins. The spots that were detected at around 150kDa region of the 2D gel were 
identified as IgG by Western blot technique. The proteins selected for Western Blot 
validation were chosen based on their ion scores (Table 2.1). The Western Blot study 
confirmed the identity of not just proteins with the highest ion score e.g. Caspase-14 
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protein 5 IPI00021536 15910.78 99.9471103 
 
205.2 34 3 2D-LC-MS/MS# 
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 S100A9 Protein 




 S100A7A Protein 
S100-A7A IPI00328396 11297.54 98.3504266 
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protein IPI00075248 16495.881 100 126.94 32 2 2D-LC-MS/MS# 
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S100A8 Protein 
S100-A8 IPI00007047 10885 100 170 50 7 2DE 
Enzymatic proteins   
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2 of Heat shock 
cognate 71 kDa 
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 CTSD Cathepsin 
D precursor IPI00011229 44523.621 100 
232.58/36






precursor IPI00000013 37305.121 98.3896357 50.77 7 1 2D-LC-MS/MS# 
13 
 CTSA cathepsin 
A precursor IPI00640525 56196.941 99.9996221 
  
183.58 7 3 2D-LC-MS/MS# 
14 
 CTSB Cathepsin 








 CTSH Cathepsin 





precursor IPI00023728 35941.172 99.9942201 68.21 12 1 2D-LC-MS/MS# 




thioesterase 1 IPI00514248 23196.57 99.6612151 50.53 5 1 2D-LC-MS/MS 
20 
 LTF 73 kDa 





Ubiquinol- IPI00296022 10731.94 100 
  









 SERPINB7 14 
kDa protein IPI00021555 14089.89 99.9511433 58.94 15 1 2D-LC-MS/MS 
                                      Immune function proteins   
23 
IGHA2 Ig alpha-2 
chain C region IPI00783993 36485.051 98.0304288 139.94 11 2 2D-LC-MS/MS# 
24 




9 IPI00423466 52818.609 100 163.15 16 2 2D-LC-MS/MS# 
25 
 HLA-DRA major 
histocompatibility 
complex, class II, 
DR alpha 
precursor IPI00464948 28602.711 99.9998926 
  





precursor IPI00022810 51808.25 100 
  




2 precursor IPI00020091 23587.631 100 153.67 17 3 2D-LC-MS/MS 
Metal ion binding proteins 
28 
 ALB Isoform 1 
of Serum albumin 
precursor IPI00745872 69321.492 100 
  
523.33 34 7 2D-LC-MS/MS# 
29 Zinc- alpha-2- IPI00166729 34237.102 100 678.07/59 58 23 2D-LC-
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glycoprotein 1 MS/MS#/2DE/WB 




protein IPI00643202 48415.18 100 126.72  12 2 2D-LC-MS/MS# 
31 
Dermcidin 
isoform 2 IPI00847793 12406.45 100 
  
91.68 20 1 2D-LC-MS/MS# 
32 
 SERPINB10 
Serpin B10 IPI00010304 45373.957 95.1985591 39.14 9 1 2D-LC-MS/MS 
33 
 HSPA5 HSPA5 
protein IPI00003362 72377.461 100 99.87 8 1 2D-LC-MS/MS# 
34 
 CLU clusterin 
isoform 1 IPI00400826 57795.59 94.1126524 38.13 11 1 2D-LC-MS/MS 
35 
 MYCBP2 
Isoform 2 of 
Probable E3 
ubiquitin-protein 
ligase MYCBP2 IPI00289776 509382.91 99.9929382 
  
67.34 4 1 2D-LC-MS/MS 
36 




3a precursor IPI00178767 51227.68 99.9982545 
  




inhibitor, clade B 
(Ovalbumin), 
member 6 IPI00513699 21231.33 99.6052053 35.01 3 1 2D-LC-MS/MS# 
38 
 SERPINB3 
SCCA1b IPI00307466 38525.441 100 
  
458.27 22 5 2D-LC-MS/MS# 
39 
 CAPN1 Calpain-
1 catalytic subunit IPI00011285 81838.188 99.9999483 
  








1 precursor IPI00300786 57730.91 100 
  
351.91 29 5 2D-LC-MS/MS# 
41 
 LYZ Lysozyme 
C precursor IPI00019038 16526.279 99.9911504 
  




family, member 2 IPI00646322 58445.238 100 122.26  14 2 2D-LC-MS/MS# 





inhibitor, clade B 
(ovalbumin),  IPI00749398 42936 98.584 92 49 14 2DE 
45 
 SERPINB4 
SCCA2b IPI00412407 42260.262 100 251.13 14 4 2D-LC-MS/MS# 
Structural constituent proteins 
46 
 KRT1 Keratin, 
type II 





precursor IPI00002147 42598.398 100 91.15 14 1 2D-LC-MS/MS# 
48 
 CHI3L2 chitinase 
3-like 2 isoform b IPI00607646 42481.359 99.7761672 
  
52.33 4 2 2D-LC-MS/MS# 
49 
Keratin, type I 
cytoskeletal 9 IPI00019359 62320 100 722 62 28 2DE/WB 
50 
Keratin, type II 




Keratin, type II 
cytoskeletal 5 IPI00009867 62568 100 155 16 7 2DE 
52 
Keratin, type I 
cytoskeletal 16 IPI00217963 51578 100 217 43 16 2DE 
53 
 ACTB Actin, 
cytoplasmic 1 IPI00414057 41709.73 99.9257111 57.12 12 1 2D-LC-MS/MS# 
54 
 KRT14 Keratin, 
type I cytoskeletal 
14 IPI00384444 51589.441 99.9983292 
  
73.60 18 2 2D-LC-MS/MS 
55 
 KRT2 Keratin, 
type II 
cytoskeletal 2 




Keratin, type I 
cytoskeletal 10 IPI00009865 59703 100 1440 56 31 2DE/WB 
57 
 KRT6B Keratin, 
type II 
cytoskeletal 6B IPI00293665 59962.25 99.9986561 
  
74.67 7 1 2D-LC-MS/MS 
58 
 KRT6C Keratin, 
type II 
cytoskeletal 6C IPI00299145 59988.301 100 
209.93/17
3 33 19 
2D-LC-
MS/MS/2DE 
59  KRT4 keratin 4 IPI00290078 63871.359 99.889357 
  
55.39 9 1 2D-LC-MS/MS 




precursor IPI00744184 53553.672 99.9958703 
  




receptor precursor IPI00004573 83231.648 100 
  
195.13 16 3 2D-LC-MS/MS# 
Inhibitor proteins 






SN precursor IPI00305477 16351.33 100 
  
165.62 56 3 2D-LC-MS/MS 
64 
 CST4 Cystatin-S 
precursor IPI00032294 16203.97 100 339.68  80 6 2D-LC-MS/MS# 
65 
 CSTA Cystatin-
A IPI00032325 10999.66 100 
115.63/39











precursor IPI00018236 20808.76 100 161.5 16 1 2D-LC-MS/MS# 
68 
 GRN Isoform 1 
of Granulins 
precursor IPI00296713 63499.84 100 101.9 3 1 2D-LC-MS/MS# 
69 
 CREG1 Protein 





Thioredoxin IPI00216298 11729.74 100 155.6  57 2 2D-LC-MS/MS# 
71 
 UBA52 ubiquitin 
and ribosomal 
protein L40 






precursor IPI00003919 40850.809 99.9998306 
  
83.54 8 1 2D-LC-MS/MS 
73 
 GAA Lysosomal 
alpha-glucosidase IPI00783446 105270.8 99.9334843 
  
























precursor IPI00022974 16561.801 100 
569.45/46






precursor IPI00007778 43731.59 99.9999396 
 
88.02 9 1 2D-LC-MS/MS# 
80 
 IGLV4-3 
IGLV4-3 protein IPI00382938 25960.699 100 
 






precursor IPI00001469 9918.3398 100 
 




precursor IPI00219476 47145.012 100 
 
115.24 11 1 2D-LC-MS/MS# 
83  - 20 kDa protein IPI00790298 19533.881 99.8694057 54.67 16 1 2D-LC-MS/MS 
84 
 - Actin-like 
protein 




 C3 187 kDa 
protein IPI00164623 187187.94 99.9961371 69.96004 3 1 2D-LC-MS/MS 
86 
 CA6 Carbonic 
anhydrase VI nirs 
variant 3 IPI00554696 28679.51 99.999821 
  
83.3 14 1 2D-LC-MS/MS 
87 
 DTD1 Probable 
D-tyrosyl-
tRNA(Tyr) 





LOC29094 IPI00023549 18973.65 100 128.73 19 2 2D-LC-MS/MS 
89 
 KLK11 Variant 
form 
hippostasin/KLK1












15 IPI00060800 18866.67 100 
  
90.66 23 2 2D-LC-MS/MS 
92 
 LYPD3 Putative 
uncharacterized 
protein 
DKFZp686D0114 IPI00643788 30478.24 100 
  
219.33 11 2 2D-LC-MS/MS 

















2DE: 2D gel & MALDI-TOF/TOF. 
WB: Western Blot 
# Proteins identified in both the runs of 2D-LC-MS/MS. 
 
* 2D-LC-MS/MS Total ion score and/or 2DE protein score. 
1: % Sequence Coverage 
2: Unique peptides




 PEBP1 22 kDa 




idase isoform 2 
preproprotein IPI00399307 58062.18 100 
  
111.63 6 1 2D-LC-MS/MS 
96 
 SBSN 
Suprabasin IPI00373937 60504.59 99.9996137 
  
79.96 10 2 2D-LC-MS/MS 
97  TF 8 kDa protein IPI00022463 7679.8198 99.9998819 85.23  17 1 2D-LC-MS/MS 
98 
 TF Transferrin 
variant 
(Fragment) IPI00798430 77029.594 100 
  





F ig 2.5 Western blot validation of sweat proteins.  Some of the major proteins identified by 2DE and 2D LC-MS/MS 





The main focus of this study was to identify and document the repertoire of 
proteins present in healthy human sweat. For this 2DE coupled with MALDI 
TOF/TOF and 2D-LC-MS/MS techniques which are known to be powerful techniques 
for identification of proteome profile present in biological fluids was used. 
 
The mass spectrometry analysis of sweat proteins has not only identified  
proteins that were previously known to be present in sweat but also those that have not 
been documented so far as a part of the sweat proteome. Proteins previously known to 
be present in sweat include proteins such as Cystatin A (Kato et al., 2005), Psoriasin 
(Glaser et al., 2005), Dermcidin (Birgit et al., 2001) and Zinc-alpha-2-glycoprotein 
(ZAG) (Sanchez et al., 1997). This study has identified presence of numerous other 
proteins (Table 2.1) apart from those reported to be present previously.  
 
As mentioned above, a total of 98 unique proteins were identified by 
combining both methods.  Most of these proteins fall into classes that have important 
biological functions as shown in Fig 2.4. One of the most abundant proteins present in 
sweat is structural constituent proteins like Keratins. Mass spectrometry results 
suggest that sweat contains numerous forms of keratins. This can be attributed to the 
fact that sweat is deposited on the skin. The outermost layer of human skin is called 
Stratum corneum, which are mainly composed of dead cells. As these cells slough off 
they are replaced by new cells. Cells of the stratum corneum contain keratin and hence 
it is not surprising that most of the proteins found in human sweat are keratins since 
sweat is deposited onto the skin. 
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The second most abundant protein found in human sweat is Zinc- alpha-2-
glycoprotein 1 (ZAG). ZAG has been known to be present in body fluids such as 
sweat, saliva, cerebrospinal fluid, seminal plasma, milk, amniotic fluid, and urine 
(Luis M et al., 1997). Previous reports have shown that ZAG shares 30±40% sequence 
identity with the heavy chains of class I major histocompatibility complex (MHC) 
proteins (Luis M et al., 1997). It has been reported that ZAG is involved in the 
depletion of fat in cancer patients with cachexia (Luis M  et al., 1999). 
 
This study has also identified a few proteins belonging to the S100 family such 
as Calgranulin A (S100A8), Calgranulin B (S100A9) and the previously reported 
protein Psoriasin (S100A7) (Glaser et al., 2005). S100 proteins comprise of a family 
of low molecular weight proteins consisting of two calcium-binding EF-hand motifs. 
Calgranulin A (S100A8) also known as MRP8 and Calgranulin B (S100A9) also 
known as MRP 14 has been reported to be released from neutrophils and may enhance 
inflammation.  S100A7 on the other hand has been shown to be antibacterial against 
E .coli (Glaser et al., 2005). 
 
Among the proteins found in the low molecular weight range Cystatin A was 
found to be one of the most abundant. Cystatin A is an inhibitor of cysteine 
proteinases. It has been shown that Cystatin A inhibits the proteolytic activity of house 
dust mite Der p 1 and Der f 1 thus acting as a biochemical skin barrier (Kato et al., 
2005). The other inhibitors found in sweat are those belonging to the Serpin family- 




The sweat proteome also detected the presence of a few enzymes such as 
Cathepsin D, an aspartyl peptidase which is involved in intracellular digestion of 
proteins and peptides within lyososmal compartments (Fusek et al., 2005). 
 
Some of the other enzymes shown to be present in sweat are Superoxide 
Dismutase (SOD1), Protein-glutamine gamma-glutamyltransferase E precursor 
(TGM3), Carboxypeptidase E precursor (CPE). Prolactin inducible protein (PIP) that 
was identified in 2D and 2D-LCMS/MS is a small secretory protein with unknown 
function.  
 
This study has lead to the identification of a wide array of proteins present in 
healthy human sweat falling into a broad spectrum of functional classes (Fig 2.4). 
Some the proteins known to be present in human sweat have been shown to have 
antibacterial activity (Psoriasin and Dermcidin), while some have been reported to 
form a biochemical skin barrier against the proteolytic activities of the dust mite, 
hence proving that the proteins present in sweat have a defined role and function. 
Gene ontology studies on the identified 98 proteins indicate that these proteins fall 
into groups with diverse functions such as (Fig 2.4) enzymatic, immune function, 
enzyme inhibitors, metal binding, calcium ion binding etc.   
 
We are all aware that an intact skin forms a first line of defence against the 
vast spectrum of pathogens present in the environment. But just an intact skin is not 
sufficient to combat the harmful effects of the micro-organisms, and so is the fact that 
just a few antimicrobial peptides are not sufficient to resist the potential threat that 
these micro-organisms have on the human body. This study shows that sweat which is 
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secreted and deposited on the outermost surface of the skin contains proteins with 
diverse roles. Identification of the proteins present in sweat points us to a possible 
hypothesis that a few of these proteins may act alone or in synergism with the other to 
prevent infections or may have other potential protective role, thus forming an 
important part of the innate immune system.  Studies have shown that patients with 
atopic dermatitis (AD) have reduced expression of the antimicrobial peptide 
Dermcidin which increases their susceptibility to skin infections (Rieg et al., 2005). 
This further supports the hypothesis that some of the proteins identified in sweat could 
possibly have an antimicrobial function apart from those that are previously known. 
 
As mentioned previously some of the low molecular proteins S100 proteins 
that have been identified in the sweat include S100 A7, S100 A8 and S100 A9 and 
S100 A7 has been reported to be an AMP. Interestingly it has been  proposed that 
S100A8 and S100A9 may have a role in promoting  hyperproliferative state in the 
epidermis, as S100A8 and S100A9 shows a marked increase in expression  during the 
first week of skin injury (Thorey et al., 2001), thus suggesting that sweat not only 
contains proteins with antibacterial activity but also harbours proteins with wound 
repair function. .  
 
The strategy employed in this study, i.e. to use 2DE followed by MALDI 
TOF/TOF MS and 2D-LC-MS/MS proved to be an efficient technique to identify 
sweat proteins and these methods are complementary.  A further confirmation using 





There is a growing interest in using body fluids such as tears (Zhou et al., 
2004), urine (Rembert et al., 2004), saliva (Tong et al., 2006 ) etc for diagnostic 
purposes due to relatively simple and non-invasive collection procedures. Sweat test 
still continues to be the widely used test for detection of Cystic Fibrosis. This study 
presents initial efforts towards identification and cataloguing the proteins present in 
sweat using 2DE and mass spectrometry approaches. 2DE study coupled to MALDI-
TOF/TOF detected the presence of high molecular weight proteins >55kDa such as 
Keratins and also low molecular weight proteins <20kDa such as the S100 family of 
proteins, Cystatin A, PIP etc. The 2D-LC-MS/MS study not only detected some 
proteins identified by MALDI-TOF/TOF but also identified many other proteins thus 
aiding in the documentation of the complete array of proteins present in healthy 
human sweat.  It is important also to note that while this study presents the proteome 
profile of pooled human sweat, the levels of the individual proteins will vary amongst 
individuals. 
 
The results obtained in this study highlights the potential use of human sweat 
for diagnostic and therapeutic purposes thus opening new avenues for research studies 








C H APT E R 3: IDE N T I F I C A T I O N O F A N T I M I C R OBI A L 
C O MPO N E N TS IN H U M A N SW E A T 
3. 1 Introduction 
 
3.1.1 Antimicrobial Peptides (A MP) 
 
 
All multicellular organisms are made up of physical barrier that functions to 
protect them from the constant physical and the microbial challenges posed by the 
environment. The microbial challenges pose a major threat to the healthy well-being 
of humans as it may lead to mild symptoms or lethal consequences. An intact healthy 
human skin has two distinct functions: 1) control and inhibit the colonization of 
pathogenic microbes and 2) elicit an increased antimicrobial activity in cases of 
epidermal injury or microbial insult. Thus skin forms one of the most important line of 
defense against the invading pathogen responsible for maintaining epidermal integrity 
and keeping microbial threats at bay by mounting an array of antimicrobial peptides 
(AMP). 
 
Antimicrobial peptides are an integral component of the innate defense system. 
The innate immune system provides a broad spectrum of antimicrobial peptides to 
rapidly eliminate the invading pathogen. This property is distinct from that of the 
adaptive immune response in which the host response is initiated only after antigen 
processing by MHC and stimulation of a subpopulation of lymphocytes.   
 
Reports suggest that the components of the innate immune system may act as 
signaling molecules for the adaptive immune response. This may be particularly 
important when the microbial numbers are so high that it impends the local defenses 




The components of innate immunity are constitutively expressed or are 
inducible. Unlike the adaptive immune response which may take a period of a few 
days to weeks for mobilization, specificity and immunologic memory to develop.  
 
Microbes have evolved a vast array of mechanisms to invade the skin and 
cause diseases. The microbes possess a wide range of virulence factors making it 
necessary for the host to use numerous defense tools for protection.  Though the 
physical barrier is important, there are many microbes that have developed 
mechanisms to breach this barrier and establish an infection.  To counter the 
deleterious effects of the microbes, multicellular organisms have evolved a repertoire 
of AMP. These AMP, protect the human system from pathogen entry. These AMP 
also act as the first line defense barrier to keep microbial growth under check. 
 
3.1.2 Properties and diversity of antimicrobial peptides 
 
AMP was first described in the 1970s and 1980s as molecules encoded by 
genes which confer disease resistance to plants and insects. The identification of 
defensins in neutrophil granules, lead to the understanding that similar peptides might 
also exist in the mammalian immune system. As the complexity of the immune 
defense systems of mammals unravels, the apparent role of AMP in host defense is 
gradually becoming clear. 
 
So far more than 700 AMPs have been documented to be present in diverse 
species such as plants, insects, amphibians and mammals. The most common feature 
observed in most of these AMPs is that they are cationic and form amphipathic 
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structures (Schittek et al., 2008).  AMPs have been shown to have a broad spectrum 
activity against bacteria, fungus, and enveloped viruses thus forming an important part 
of the innate host defense. The exact mechanism of action of most AMPs is still 
unclear but it is generally suggested that the AMPs may cause one/more of these 
effects to kill the invading pathogen: 
1. Increase the permeability of bacterial cytoplasmic membrane. 
2. Chemotaxis of immune cells such as macrophages, dendritic cells and T cells. 
3. Sequestering essential nutrients required by the pathogen. 
4. Act as signaling molecules linking adaptive and innate immune response. 
 
3.1.3 Antimicrobial Peptides in human eccrine sweat 
 
The preliminary studies on human sweat showed that it is composed of 
proteins apart from salts and urea (Marshall et al., 1984). But, even more interesting 
was the fact that human eccrine sweat consists of the AMP Dermcidin, an AMP which 
is constitutively expressed by the sweat glands (Schittek et al., 2001). The presence of 
an AMP in sweat proved that the role of sweat is not limited to just thermoregulation 
and homeostasis but also in defending the body against microbial threats.  Though it is 
known that skin harbors numerous AMP that are active against the invading pathogen, 
it is also well known that most of these skin AMP are produced only after injury or an 
inflammatory response i.e. they are inducible proteins.  Hence proteins like Dermcidin 
that are constitutively expressed are of pivotal importance for preventing microbial 




In an attempt to characterize the human eccrine sweat proteome, a 2DE 
followed by MALDI-TOF/TOF and 2D-LC-MS/MS was performed and it was 
observed that healthy human sweat consists of approximately 98 unique proteins 
(Table 2.1).  It would be interesting to understand the functions of the same with 
respect to their role in immune defense. A few of the proteins that have been identified 
in sweat have been previously shown to have antimicrobial activity e.g. Dermcidin 
and, Psoriasin (Schittek et al., 2008).   
 
As mentioned previously, human skin is constantly challenged by disease 
causing pathogens present in the environment. Despite this, skin is surprisingly highly 
resistant against infections. This is because of the cutaneous defense system which 
produces numerous AMP that provides a fast and effective means to prevent microbial 
colonization and thus subsequent infections.  Since the antimicrobial function forms 
the first line of defense it would be interesting to know if the healthy human eccrine 
sweat consists of any other AMP apart from those reported so far. The vast array of 
microbial threats that we face constantly cannot be dealt with just by the presence of a 
few AMP, hence it was hypothesized that of the 98 unique proteins that have been 
identified in sweat there could be proteins with antimicrobial activity which needs to 
be understood and characterized. 
 
3.1.4 Objectives of this study 
 
In this study it was aimed to identify the presence of proteins with 
antimicrobial activity in sweat. For this, healthy human sweat was collected and the 
proteins were separated into fractions by Reversed Phase-High Performance Liquid 
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Chromatographic (RP-HPLC). Each of the fractions was then tested for its 
antimicrobial activity against a broad spectrum of Gram negative, Gram positive and 
fungal pathogens. The pathogens that were included in the screening study included 
Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus 
epidermidis, Proteus vulgaris, Klebsiella pneumoniae, Streptococcus pyogenes, 
Enterococcus faecalis and Candida albicans. These organisms were selected as they 
are known to cause skin infections and/or are commonly encountered pathogens 
(Table 3.1). The fractions that showed a positive antimicrobial response were later 
identified by Dot blot. These proteins were further cloned and expressed to produce 
recombinant proteins to help understand their function. Human sweat is known to 
contain high amounts of salt and also has an acidic pH. To strengthen support for the 
antimicrobial function, the recombinant proteins were also tested for their functional 
stability at varying pH and salt concentrations.  
 Pathogens Diseases caused 
G ram positive bacteria 
Staphylococcus aureus Impetigo, Staphylococcal scalded skin syndrome & folliculitis 
Staphylococcus epidermidis Skin lesions 
Streptococcus pyogenes, Impetigo, Erysipelas 
Enterococcus faecalis Wound infections 
G ram negative bacteria 
Pseudomonas aeruginosa Dermatitis and pyoderma 
Klebsiella pneumoniae, folliculitis, 
 Proteus vulgaris, folliculitis, 
Escherichia coli, Diarrhea 
Fungus  
Candida albicans Cutaneous candidiasis 











3.2 M ater ials and M ethods 
 
 
3.2.1 Collection and concentration of sweat proteins 
 
 
Healthy human sweat was collected using the method as described in sections 2.2.1 
and 2.2.2. 
 
3.2.2 Antimicrobial activity of sweat proteins 
 
Crude and lyophilized sweat which was later dissolved in solubilising buffer 
was tested for antimicrobial activity against E .coli and the fungus C . albicans using 
the Disc diffusion test. Briefly, E .coli was grown in Luria Bertani (LB) broth while C . 
albicans ZHUH JURZQ LQ 6DXERXUDXG¶s broth. Microbial cultures were activated by 
inoculating in 1 ml of LB broth and overnight incubation in a shaker for 15 hours set 
at 37oC. Actively growing cells were obtained by transferring 20ȝl of this log phase 
culture into 900ȝO of fresh LB broth followed by further incubation at 37oC for 15 min 
in a shaker. The cell suspension of 107 cells/ml was prepared. Sterilized cotton swabs 
made in-house were used to obtain a lawn of growth on the plate by swabbing the 
culture on to the plate. Sterilized paper disks (6 mm in diameter) prepared from 
western blot filter paper were dipped into crude sweat and solubilised sweat samples 
and placed onto the swabbed plate. The plates were incubated at 37oC overnight. 
Zones of inhibition were measured and documented.  
 
3.2.3  RP-HPL C fractionation 
 
Separation of lyophilized sweat proteins was carried out by RP-HPLC using 
AKTA purification system (Amersham Pharmacia Biotech) on a Jupiter C18 column 
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(250 x 4.6 mm $ SRUH VL]H ZLWK ȝP SDUWLFOHV. The flow rate was set at 0.8 
ml/min.  Solvent A was 0.055% aqueous trifluoroacetic acid; solvent B was 80% 
acetonitrile in 0.05% aqueous trifluoroacetic acid. The gradient used was 0-20% 
acetonitrile for 20 min, 20-60% acetonitrile for 30 min and 60-80% acetonitrile for 30 
min was used for optimum separation.  The fractions were concentrated using a speed 
vac for 2 hrs. 
 
3.2.4  Antimicrobial activity assay 
 
Antimicrobial activity of the separated sweat fractions was tested using the 
disk diffusion method. Activity against Escherichia coli, Staphylococcus aureus, 
Pseudomonas aeruginosa, Staphylococcus epidermidis, Proteus vulgaris, Klebsiella 
pneumoniae, Streptococcus pyogenes, Enterococcus faecalis and Candida albicans 
(all organisms were clinical isolates and kind gifts from the Department of 
Microbiology, NUS) were assessed. Bacteria were grown in Luria Bertani (LB) 
medium while C . albicans ZHUH JURZQ LQ6DXERXUDXG¶s medium. Negative controls 
included solubilising buffer for lyophilized sample, solvent B, distilled water. 
Ampicillin served as positive control: 1 mg/ml for S. aureus, S. epidermidis P. 
vulgaris, E . faecalis, S pyogenes; 5mg/ml for E . coli and 12 mg/ml for P. aeruginosa. 








3.2.5  Dot blot identification of the positive fractions 
 
ȝl of each positive fraction suspended in HPLC solvent B were dotted onto 
Nitrocellulose membranes (Bio-Rad Laboratories Inc.). The dried membranes were 
blocked with 4% non-fat milk overnight at 4oC. Mouse anti-human monoclonal 
antibodies were used for identification (the antibodies used were as indicated in 1.2.8). 
Each of the antibodies were appropriately diluted using PBS and added to the 
membranes and incubated for 2.5 hours. The membranes were washed with PBST, 
followed by incubation at room temperature for 2 hours with rabbit anti-mouse 
secondary antibody conjugated to horseradish peroxidase (BD Pharmingen) at a 
1:2000 dilution. The blots were developed using enhanced chemiluminescence system 
(ECL; Amersham Pharmacia). 
 
3.2.6  PC R amplification and expression of candidate sweat proteins 
 
The sweat fractions which showed a positive antibacterial activity were 
identified and it was decided to clone and express the same to further characterize and 
understand the function of these antimicrobial proteins. The clones were purchased 
from Open Biosystems Inc. in vector form. The plasmids were extracted as per 
manufacturer instruction. Briefly, each of the clones were inoculated into LB medium 
(with ampicillin or chloramphenicol DVSHUPDQXIDFWXUHU¶VLQVWUXFWLRQV) and incubated 
overnight in a shaker at 37oC .  Plasmid  were extracted using Qiaprep Spin Mini prep 
kit (QIAGEN Inc.). The  Genes of interest was amplified using Expand Long 
Template PCR System (Roche Diagnostics) as follows-0.5ʅl of each primer (100uM), 
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ȝO RI ; EXIIHU ȝO of dNTP (10uM), 10 ng of plasmid DNA and 0.5ȝl of BD 
Advantage TM polymerase (BD Biosciences). The primers used were as follows: 
Cystatin A_f¶-GAA TTC ATG ATA CCT GGA GGC TTA TC-¶ 
 
Cystatin A_r:¶-GGA TCC CTA AAA GCC CGT CAG-¶ 
 
Psoriasin _f: ¶-GAA TTC ATG AGC AAC ACT CAA GCT GA-¶ 
 
Psoriasin _r: ¶-GGA TCC TCA CTG GCT GCC C-¶ 
 
Clusterin_f: ¶-GAA TTC ATG ATG AAG ACT CTG CTG C-¶ 
 
Clusterin_r: ¶-GGA TCC TCA CTC CTC CCG G-¶ 
 
Lactofer rin_f: ¶-GAA TTC ATG AAA CTT GTC TTC CTC GT-¶ 
  
Lactofer rin_r: ¶-GGA TCC TTA CTT CCT GAG GAA TTC -¶ 
 
Z A G_f: ¶-GAA TTC ATG GTA AGA ATG GTG CCT -¶ 
 
Z A G_r: ¶-GGA TCC CTA GCT GGC CTC C -¶ 
 
SO D1_f: ¶- AAT AAG GAT GAT CCA TGG CGA CGA AGG  CCG-¶ 
SO D1_r: ¶- AAT AAG AAT TCT TAT TGG GCG ATC CCA ATT ACA C-¶ 
 
All thermal cycle steps were carried out using the PTC-100TM Programmable 
Thermal Controller (MJ Research, Inc.) PCR  machines. Cycle conditions were as 
follows: denaturation at 940C for 5 min, 35 cycles of 940C for 10 sec, 500C for 30 sec; 
680C for 1 min and a final 5 min at 680C. Gel electrophoresis was carried out using 
1% agarose in tris-acetate-EDTA (TAE) buffer (40mM Tris-acetate, 1mM EDTA, pH 
7KH*HQH5XOHUNE'1$/DGGHU0%,)HUPHQWDVZDVORDGHGDVDVWDQGDUGIRU
comparison. The required PCR product was obtained by gel extraction using 
4,$TXLFN *HO ([WUDFWLRQ .LW 4,$*(1 ,QF 7KH *HQH5XOHU NE '1$ /DGGHU
(MBI Fermentas) was loaded as a standard for comparison. The DNA obtained was 
46 
 
quantified  XVLQJ WKH 6PDUW6SHF 3OXV 6SHFWURSKRWRPHWHU %LR-Rad Laboratories 
Inc). 
 
3.2.7  Double digestion and insertion of the gene of interest into vector  
 
DNA inserts were sub-cloned into pET-M vector, a modified pET-32a plasmid 
(Novagen) with S-tag and thioredoxin tag removed. The digestion of DNA insert was 
carried out by digesting 0.5ȝJPCR productȝO BamH1 and ȝO EcoR1 restriction 
enzymes (New England Laboratories), 5ȝO 10X buffer 2 (New England Laboratories) 
LQDWRWDOYROXPHRIȝO.  The mixture was then incubated at 370C for 1 hour. In a 
VHSDUDWHWXEHWKHVDPHUHDFWLRQPL[WXUHZDVVHWXSXVLQJȝJYHFWRUDQGLQFXEDWHG
370C for 1 hour. Ligation was carried out at 120C for 16 hours using 1:3 vector: insert 
UDWLRȝO 10X PCR buffer, ȝOT4 DNA ligase (Promega) in DWRWDOYROXPHRIȝO. 
 
3.2.8 T ransformation of ligation mixture into X L1 blue competent cells 
 
Ligation reaction was added into 50ȝl of XL1 blue competent cells and kept on 
ice for 40 minutes. Heat shock transformation was carried out by incubating the cells 
at 42°C for 90 seconds, followed by 2 minutes on ice. 900ȝORI/%EURWKZDV added 
into the tubes before incubation at 37°C in water bath for 1 hour. Cells were spun at 
6,000 rpm for 2 minutes and 900ȝORIWKHVXSHUQDWDQWZHUHUHPRYHG&HOOSHOOHWZDV 






3.2.9  Screening for positive inserts 
 
Proper insertion of DNA insert into target plasmid was verified by PCR 
screening of colonies grown on LB-ampicillin agar plate. Several colonies from each 
plate were selected for the screening. Half of a colony was picked using a sterile 
yellow tip and re-suspended with 6ȝO of sterile water in an eppendorf tube. 1ȝO of the 
supernatant can be used DNA template for PCR reaction. A PCR reaction cocktail 
containing 15ȝO of 10X Buffer, 3ȝl of 10mM dNTP, 3ȝl of 10ȝM forward primer, 3ȝl 
of 10mM reverse primer, 9ȝl of 25mM MgCl2 and 1.5ȝl of Taq polymerase (Promega) 
in total volume of 100ȝl. The cycling conditions were set at 95ºC for 5mins, followed 
by 35 cycles of denaturation (94ºC for 30s), annealing (50ºC for 30s) and extension 
(72ºC for 1min if the insert size was less than 1kb). Final extension was carried out at 
72ºC for 5min.  
 
3.2.10  Isolation of plasmid DN A  
 
Colonies that showed positive PCR screening results were cultured overnight 
in 5ml LB broth supplemented with 100ȝJPODPSLFLOOLQLQD&VKDNHU&HOOSHOOHWV
from 5 ml of overnight culture were recovered by centrifugation at 6,000 rpm for 15 
minutes. DNA plasmid was extracted from pelleted cells by using QIAGEN Miniprep 







3.2.11 Plasmid DN A sequencing 
 
  Sequence confirmation was carried out by setting up the following reaction 
mixture-2ȝl of plasmid DNA (250ng) added with 3ȝO RIZDWHU ȝl of the Big Dye 
Terminator, 3ȝl of 5x Sequencing Buffer and 2ȝl RI 7 SULPHU ȡ0 7KH PCR 
cycles consisted of 30 cycles: 10sec at 96ºC, 15sec at 50ºC and 4 min at 60ºC. The 
amplified DNA was then purified by adding 2ml 125mM EDTA, 3ȝO 3M sodium 
acetate, pH 4.6, 62.5ȝl of 95% ethanol and 14.5ȝl autoclaved water. The suspension 
was left at room temperature for 15 min and then centrifuged at 13,000 rpm for 20min. 
Supernatant was discarded and 500ȝl of 70% ethanol was added and centrifuged again 
at 13,000 rpm for 5min. Supernatant was discarded and sample was air-dried  at room 
temperature and stored at 4°C till further use. Just before loading onto the ABI 
PRISM® 3100 Genetic Analyzer (Applied Biosystems Inc.), 15ȝl of autoclaved 
distilled water was added to rehydrate the sample. 
 
3.2.12 Protein expression  
 
A single colony of E . coli BL21 cells containing the desired plasmid was 
picked and cultured overnight in 10 ml of LB broth containing 100 ȝg/ml ampicillin.  
The 10ml culture was transferred into 1l of fresh LB broth containing ampicillin 
ȝJPODQGJURZQ in a shaker set at 37°C, 75rpm for 4hr. Protein expression was 
induced by the addition of 1ml of 0.5M isopropyl 1-thio-ȕ-Dgalactoside (IPTG) and 
further overnight incubation in a shaker set at 22°C and 75rpm. The cells were 
harvested by centrifugation at 10,000 rpm for 15 min at 4°C. The cell pellet thus 
obtained was re-suspended in 25ml of binding buffer consisting of 40mM imidazole, 
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4M NaCl, 160mM Tris-HCl at pH7.9. The re-suspended cells were lysed by 
sonication on ice for 5 x 45s with 38% sonication amplitude.  The proteins thus 
released was then later collected by centrifugation at 18,000rpm for 30min at 4°C.  
 
3.2.13 Affinity Purification 
 
 The His-tagged recombinant proteins were purified by affinity chromatography 
using Ni-NTA His·Bind resin (Novagen).  The proteins obtained from the previous 
step were incubated with approximately 6ml of charged Ni-NTA resin (Novagen) for 
about 2hr at 4°C and then loaded into Ni-NTA columns (Bio-Rad Laboratories Inc). 
The proteins bound to the resin was washed 6 times with binding buffer (40mM 
imidazole, 4M NaCl, 160mM Tris-HCl at pH7.9) and 10 times with wash buffer 
(60mM imidazole, 0.5M NaCl, 20mM Tris-Cl at pH 7.9). Later the purified protein 
was eluted with 5ml of elution buffer (1M imidazole, 0.5M NaCl, 20mM Tris-Cl at 
pH 7.9). The eluted purified recombinant proteins were dialyzed overnight against 
50mM sodium phosphate buffer, pH 7.4 at 4°C, and stored at -80°C till further use. 
The purified recombinant proteins were quantified using the Bio-Rad Protein Assay 
(Bio-5DG /DERUDWRULHV ,QF RQ WKH 6PDUW6SHF 3OXV spectrophotometer (Bio-Rad 
Laboratories Inc) with bovine serum albumin (BSA) as standard. 
 
3.2.14  Sodium Dodecyl Sulfate Polyacrylamide Gel E lect rophoresis (SDS-PA G E)  
 
 The protein purity was checked by running a SDS-PAGE. The  protein gels 
were stained with Coomassie Brilliant Blue (0.25% (w/v) Coomassie Brilliant Blue 
R250 staining solution, 10% (v/v) glacial acetic acid, 50% (v/v) methanol) for 50min 
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and then destained overnight in the methanol/acetic solution without dye. The sizes of 
the purified proteins were determined by comparing with the Broad Range Pre-stained 
Protein Marker (Bio-Rad Laboratories). 
 
3.2.15 A lamar Blue assay 
 
Microbial culture was grown as described in section 3.2.4 and the cell density 
was adjusted 105 cells/ml with final well volumes of 100ȝl in a flat bottom 96 well 
plate (Nunc). Microbial cultures were then exposed to expressed and purified proteins 
incubated for 3 hr at 37°C. Alamar Blue (Biosource) was then added aseptically to the 
culture and incubated for 4 hours. Absorbance was measured at wavelengths 570nm 
and 600nm. Media, media with phosphate buffer, media with cells were used as 
controls. To study effect of varying salt concentrations on the stability of proteins, 
proteins were treated with varying NaCl concentrations (40mM ± 160mM NaCl) for 4 
hours prior to assay. To study effect of varying pH the proteins were treated with 
phosphate buffer at different pH. Percentage growth of the microbes was calculated 











3.3 Results and Discussions 
 
3.3.1 Antimicrobial activity of human sweat proteins 
 
 The main objective of this study was to identify the AMP present in sweat. So 
far the AMP, Dermcidin (Schittek et al., 2001) and Psoriasin (Glaser et al., 2005) have 
been reported. This study aimed to identify any other antimicrobial proteins present in 
sweat that have not been identified so for. For this, the dialyzed and lyophilized 
pooled sweat was solubilised and the antimicrobial activity was tested on the Gram 
positive bacteria E .coli and the fungus C .albicans using the Disc Diffusion assay. In 
this assay the test microorganism is grown on a nutrient agar plate to obtain a lawn of 
growth. Discs are dipped in the test solution and placed on the plate. A clear zone 
around the discs showing no growth of the bacteria/fungus indicates that the solution 
absorbed on the disc has antimicrobial activity. Solubilising buffer and antibiotics 
were used as negative and positive controls respectively.  
 
F ig 3.1 Testing of crude dialyzed and lyophilized sweat for antimicrobial activity 
using Disc diffusion assay. (A) Testing the antibacterial activity against E .coli- (a) 
dialyzed sweat, (b) crude sweat, (c) lyophilized and solubilised sweat, (d) 
Chloramphenicol (3mg/ml) (e) Ampicillin (5mg/ml) and (f) solubilising buffer. (B) 
Testing the antibacterial activity against C . albicans- (a) Amphotericin  (6mg/ml), (b) 




 The results (Fig 3.1) clearly shows that the lyophilized and solubilised sweat 
proteins show antimicrobial activity against the bacteria E .coli and the fungus 
C .albicans as seen from the zone of inhibition around the discs. Hence proving that, 
sweat has antimicrobial properties. The lyophilized sweat is a complex mixture of 
numerous proteins hence it was decided that the lyophilized and solubilised sweat 
proteins will be separated into fractions and each of the fractions will be tested against 
a broad spectrum of bacteria and fungus. 
 
3.3.2 Antimicrobial activity assay 
 
Each of the fractions obtained by RP-HPLC separation were tested for its 
antibacterial activity against a broad spectrum of micro-organisms that included Gram 
negative, Gram positive bacteria and fungus. The assay was carried out using the 
standard Disc diffusion test against the following pathogens Escherichia coli, 
Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, 
Proteus vulgaris, Klebsiella pneumoniae, Streptococcus pyogenes, Enterococcus 
faecalis and Candida albicans. The Disc diffusion assay for the fractions showed that 
fractions 38-53 consisted of proteins with antibacterial activity against Escherichia 
coli, Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus pyogenes 
and Candida albicans (Fig 3.2). No anti- microbial activity was detected against   
Pseudomonas aeruginosa, Klebsiella pneumonia, Proteus vulgaris and Enterococcus 
faecalis   in any of the fractions.  The RP-HPLC fractionation of sweat proteins 
followed by antimicrobial Disc diffusion assay clearly showed that healthy human 





F ig 3.2 The anti-microbial activity of the fractions tested against different 
pathogens using Disc diffusion assay . Fractions obtained were tested for 
antibacterial activity using the Disc diffusion method against a broad spectrum of 





F ig 3.3 The pathogenic micro-organisms that showed an inhibited growth when 




 The next step was to identify the peptides present in these fractions that were 
responsible for the antimicrobial activity. 
 
3.3.3 Identification of the positive fractions by Dot blots 
 
A Dot blot study was performed using monoclonal antibodies to determine 
the protein composition of the positive fractions. Fig 3.4 shows the identity of the 
proteins that showed antimicrobial activity. It can be noted that Psoriasin that is 




F ig 3.4 Dot blot study to determine the identity of the p roteins in the fractions 




The Dot blot also clearly proved the presence of other proteins that have 
antimicrobial activity like Clusterin, Cystatin A, Lactoferrin SOD1 and ZAG. The 
proteins identified in the Dot blot were previously identified in the proteome and 
western blot studies (Table 2.1). 
 
To further understand the nature and the function of these AMP it was 
decided that these positive candidate AMP will be cloned and expressed to obtain 
recombinant proteins and then the recombinant proteins will be further analyzed for 
their role as AMPs in human sweat. 
 
3.3.4 C loning, expression and purification of recombinant candidate A M P in 
sweat 
 Screening for the presence of AMP in sweat showed that sweat consists of 
AMPS peptides ± Cystatin A, ZAG, Psoriasin, SOD1, Clusterin, and Lactoferrin. The 
clones were amplified using primers as listed in section 3.2.6.  
 
 





The proteins were then over-expressed as a soluble His-tag protein in E. coli 
BL21 cells. The cells were sonicated and the lysate were loaded into a Ni-NTA 
column. Affinity chromatography was carried out to separate His-tagged proteins from 
other bacterial proteins. The proteins appeared as a pure single band when analyzed on 
a 15% SDS-PAGE gel stained with Coomassie blue (Fig 3.6). Cystatin A, Psoriasin 
and SOD1 could be expressed successfully at optimal concentrations while ZAG and 





F ig 3.6 Representative SDS PA G E gels of the recombinant expressed and 
purified proteins. 
 
3.3.5 Antimicrobial activity of expressed recombinant proteins 
 
In an attempt to further understand the function of the AMP present in sweat 
it was decided that the expressed proteins be tested for their antimicrobial activity. 
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Appropriate controls were used to demonstrate precisely the antimicrobial nature of 
the expressed proteins. Phosphate buffer was used as one of the controls to ensure that 
the buffer by itself had no killing effect on the test microorganisms. The results 
showed that the buffer in which the recombinant proteins were suspended had no 
killing effect on the test organisms.  
 
 For the quantitative determination of the antimicrobial activity of the candidate 
sweat proteins it was decided to use the Redox indicator dye Alamar Blue. Alamar 
Blue
 
detects cell viability by utilizing a blue and nonfluorescent dye resazurin. The 
chemical reduction of the growth medium which occurs due to the growth of the cells 
leads to the conversion of the blue and nonfluorescent dye resazurin to a pink and 




F ig 3.7 Antimicrobial activity of recombinant sweat protein Cystatin A on test 
micro-organisms represented as percentage k illing effect. Test organisms were 
grown in the presence of the recombinant protein Cystatin A, and the percentage 





F ig 3.8 Antimicrobial activity of recombinant sweat protein Psoriasin on test 
micro-organisms represented as percentage k illing effect . Test organisms were 
grown in the presence of the recombinant protein Psoriasin, and the percentage killing 




F ig 3.9 Antimicrobial activity of recombinant sweat protein SO D1 on test micro-
organisms represented as percentage killing effect . Test organisms were grown in 
the presence of the recombinant protein SOD1, and the percentage killing effect was 
determined by the addition of Redox indicator dye Alamar Blue. 
 
Using the Alamar Blue dye, the percentage killing effect of the recombinant 
candidate proteins on the different test micro-organisms was determined. As seen 
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from Fig 3.9 it is clearly evident that SOD1 has an antibacterial effect on S.pyogenes, 
while Lactoferrin shows an antibacterial effect on S.epidermidis (Fig 3.10). 
 
F ig 3.10 Antimicrobial activity of recombinant sweat protein Lactofer rin on test 
micro-organisms represented as percentage ki lling effect . Test organisms were 
grown in the presence of the recombinant protein Lactoferrin, and the percentage 
killing effect was determined by the addition of Redox indicator dye Alamar Blue. 
 
Interestingly, it is also seen that both Psoriasin and Cystatin A have an 
antibacterial effect on E .coli (Fig 3.7 & 3.8).  This study thus proves that sweat indeed 
harbors other previously unidentified proteins that have antimicrobial function. 
 
This study has lead to the identification of three novel AMP present in sweat. 
One of them is SOD1 which has an antibacterial effect against the skin pathogen 
S.pyogenes. S.pyogenes belongs to one of the most invasive skin pathogen as it can 
cause mild superficial skin infections to life threatening skin aliment. S.pyogenes is 
capable of surviving on the skin surface for extended periods making it a potent skin 
pathogen. The presence of S.pyogenes on the skin surface appears to be responsible 
for the increased susceptibility of carriers to develop impetigo. Once the bacteria 
colonize the skin surface, initial stages of infection are initiated by minor cuts and 
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scratches on the skin allowing the entry of the pathogen into the skin. These infections 
can range from minor lesion such as streptococcal impetigo, capillary dilation and 
infiltration with leukocytes to serious infections leading to purulent ulcers. S.pyogenes 
infections can also lead to Bacteremia. The streptococcal pyoderma infections are 
diagnosed by the isolation of S. pyogenes in cultures obtained from sites of skin 
infections.  The infections are generally treated with Penicillin G and Erythromycin. 
 
Incidences of prevalence of resistant S.pyogenes around the world have been 
reported (Yamanaka  et al., 2004). In this study, SOD1 has been shown as a natural 
AMP present in sweat that inhibits the growth of S.pyogenes. The presence of SOD1 
in sweat of healthy individuals makes them resistant to infections by S.pyogenes thus 
suggesting the potential use of SOD1 in therapeutics. 
 
It is interesting to note that though there have not been many reported cases of 
skin infections by S.epidermidis, but it is one of the most common nosocomial 
pathogen.  The most common sites of infection are IV lines, vascular grafts, valves, 
implants and prosthetics, i.e. those that routinely used in medical practices. The 
presence of Lactoferrin in human sweat which has been shown to have an antibacterial 
property against S.epidermidis could be the reason behind the resistance of skin 
towards S.epidermidis.  
 
It has been previously reported that Psoriasin prevents the skin from infection 
by E .coli (Glaser et al., 2005). But in this study it has been evidently shown that apart 
from Psoriasin, the protein Cystatin A present in sweat also inhibits the gut pathogen 
E .coli further protecting the skin from the same.  
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To further support the antimicrobial activity of the candidate sweat proteins it 
was decided that these proteins will be tested for their activity in conditions similar to 
that of sweat. Hence the activity of these proteins in buffers with wide range of pH 
(pH 5 to pH 8) and at different concentrations of NaCl (40 to 160nM) was tested. 
These conditions helped stimulate the conditions of sweat, thus aiding in the 
determination of the stability of the candidate antimicrobial sweat proteins.  
 
F ig 3.11 Antimicrobial activity of recombinant Cystatin A tested at varying pH 
levels represented as percentage growth of E .coli. The protein was treated with 
phosphate buffer at different pH and the activity of the treated protein was tested using 




The analysis of the effect of varying pH on the antibacterial activity of 
recombinant proteins (Fig 3.11, 3.12 and 3.13) show that the proteins retain their 
animicrobial function at a broad pH range. Thus proving that these proteins are stable 





F ig 3.12 Antimicrobial activity of recombinant Psoriasin tested at varying p H 
levels represented as percentage growth of E .coli. The protein was treated with 
phosphate buffer at different pH and the activity of the treated protein was tested using 





F ig3.13 Antimicrobial activity of recombinant SO D1 tested at varying pH levels 
represented as percentage growth of S.pyogenes. The protein was treated with 
phosphate buffer at different pH and the activity of the treated protein was tested using 






The antimicrobial activity of these recombinat proteins were also tested for 
their functional stability at varying NaCl concentrations. On testing the antimicrobial 
activity of Cystatin A, Psoriasin and SOD1, it was observed that Cystatin A and SOD1 
retain their functional stability at varying NaCl concentrations  (3.14 and 3.16) but 
Psoriasin showed a dcreased antimicrobial activity at higher concentration of NaCl 
(Fig 3.15). The possible reason for this loss of activity of Psoraisn at higher salt 





F ig 3.14 Antimicrobial activity of recombinant Cystatin A tested at varying NaCl 
concentrations represented as percentage growth of E .coli. The protein was treated 
with varying NaCl concentrations (40mM ± 160mM NaCl) for 4 hours prior to assay 








F ig 3.15 Antimicrobial activity of recombinant Psoriasin tested at varying NaC l 
concentrations represented as percentage growth of E .coli. The protein was treated 
with varying concentrations of NaCl (40mM ± 160mM NaCl) for 4 hours prior to 






F ig 3.16  Antimicrobial activity of recombinant SO D1 tested at varying NaCl 
concentrations represented as percentage growth of S.pyogenes. The protein was 
treated with varying NaCl concentrations (40mM ± 160mM NaCl) for 4 hours prior to 








 AMP are known to be endogenous antibiotics that function to kill pathogenic 
micro-organisms. But the current ongoing studies on AMP indicate that these AMP 
are not just endogenous antibiotics but have shown to activate and direct multiple 
pathways of innate and adaptive immune response. The innate defense system of an 
intact skin is greatly enhanced when the micorbial load on the skin is increased to 
alarming levels, or when the physical injury threatens to assist the microbial entry into 
the human system and establish a serious infection. 
  
 This study  was aimed to identify the presence of AMPs in human sweat apart 
from those that were previously reported. For this pooled healthy human sweat was 
collected, the proteins were concentrated and subjected to RP-HPLC fractionation. 
Each fraction thus obtained was tested for antimicrobial activity against a broad 
spectrum of  microbial pathogens that included Gram positive, Gram negative bacteria 
and fungus that commonly cause skin infections and diseases. Some of the fractions 
showed marked antibacterial activity against pathogens like S.pyogens, S.epidermidis  
and E .coli, when tested using the Disc diffusion assay.  Identification of these fraction 
by Dot blot assay revelaed that these fractions contained the proteins SOD1, 
Lactoferrin and Cystatin A respectively. This study also detected Psoriasin in one of 
the fractions that tested positive for anibacterial activity against  E .coli. To further 
understand and quantify the functionality of these proteins, they were cloned and 
recombainat proteins of the same were expressed and purified.  The functional 
quantification was established using a redox indicator dye-Alamar blue and a dose 
response study was performed. Further to support the stability of these novel 
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animicrobial proeins in sweat, the fucntionality of the same were tested in the 
presence of  a range of NaCl concentrations and also at varying pH. The results 
indicated that each of these proteins were  functionally stable under sweat pH and 
NaCl conditions except for Psoriasin that lost its activity at 160mM. 
  
The importance of this study can be appreciated by understanding the nature 
and infections caused by the pathogens that were found susceptible to the  candidate 
sweat proteins. Staphylococcus epidermidis, over the past few years has emerged as a 
common cause of nosocomial infection. These bacteria generally infect 
immunocompromised patients, those on immunosuppresive drugs, AIDS and cancer 
patients. The major point of entry for the pathogen are cathters and implants. They are 
FDSDEOH RI IRUPLQJ ELRILOPV PDNLQJ WKHP UHVLVWDQW WR KRVW¶V LPPXQH DWWDFN and 
antibiotics treatment. The pathogen can become systemic leading to sepsis. One of the 
major complication arising from S. epiermidis infections is the lack of proper 
antibiotic treatments available. In this study we have shown that S.epidermidis  growth 
is inhibited  by the sweat protein Lactoferrin. This indicates that further studies into 
Lactoferrin could pave the way for its successful establishment as a treatment of 
choice for S.epidermidis infections.  
  
The other protein that was shown to have antibacterial effect  was SOD1. 
SOD1 was shown to inhibit the growth of the pathogen Strptococcus pyogenes. 
S.pyogenes are known for producing superficial infections to invasive disease. It 
causes superficial infections of the skin such as nonbullous impetigo in infants and 
adults. Skin and throat  infection caused by S.pyogenes can lead to rheumatic fever 
and streptococcal glomerulonephritis. The elderly and people residing in densely 
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populated areas can fall prey to invasive streptococcal infection such as cellulitis and 
erysipelas. S.pyognes LV D FRPPRQ FDXVH RI  QHFURWL]LQJ IDFLLWLV RU ³ IOHVK HDWLQJ
GLVHDVH´ZKLFKFDQOHDGWRLQFUHDVHGPRUELGLW\DQGPRUWDOLW\UDWHV7KHFXUUHQWPRGH
of treatment are topical application of antibacterial ointments for superficial skin 
infections while more extensive skin infections are treated using oral anitibiotics such 
as penicillin, erythromycin. This bacteria is capable of causing diseases in 
compromised and healthy individuals alike because of the array of virulence factors it 
produces to subvert the immune system.  The indentification of SOD1 as an 
antibacterial protein against S.pyogenes  in this study opens new  avenues for the use 
of SOD1 for the treatment of S.pyogenes  infections. 
  
The other protein that showed antibacterial activity was Cystatin A, which 
showed inhibitory activity against E .coli. The other known protein with inhibitory 
activity against E .coli is Psoriasin.  
 
This study, has lead to the succesful identification of three novel antibacterial 
proteins-SOD1, Lactoferrin and Cystatin A. This study not just quantitatively 
established the  functional role of these proteins as an antibacaterial protein present in 
sweat but also showed the stability of this protein in sweat pH and NaCl 
concentrations. Though the current mode of treatment for infections and diseases 
caused by microbial pathogens are antibiotics, it is a well known fact that excessive 
use of these antibiotics can make pathogens resistant to the antibiotics. Most research 
in the field of therapeutics are focussed on the identification of novel and natural 
source of anti-microbial components. This study is one such step in the introduction of 
novel antibacterial proteins for therapeutic purposes in the treatment of skin infections 
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and diseases. Each of the proteins idenfied in this study- SOD1, Lactoferrin and 
Cystatin A could serve as replacement or complement the current antibiotics used. In 
conclusion, it can be said that these sweat proteins not just play a vital role in the 









C H APT E R 4: IDE N T I F I C A T I O N O F A N T I V IR A L 




4.1.1 Herpes Simplex V i rus-1 (HSV-1) 
 
Herpes simplex virus (HSV-1) belongs to family of Herpesviridae. The 
Herpesviridae family comprises of a large family of DNA viruses which causes 
diseases in humans and in animals. This family forms one of the major virus families, 
to which the herpes simplex, varicella zoster, and Epstein-Barr viruses belong. Viruses 
in this family have a double-stranded linear molecular DNA structure with icosahedral 
symmetry. 
 
HSV-1 causes skin and mucous membranes infections. Patients with HSV-1 
infections exhibit tiny, clear, fluid-filled blisters. Common diseases caused by HSV-1 
are oral herpes-cold sores (Herpes labialis), Herpes keratitis, and Herpes whitlow. 
 
 Approximately 40 million Americans between the ages of 15 and 75 are 
known to have been infected with HSV-1. It can infect the eyes, esophagus, trachea, 
brain, arms and legs.  HSV has a great impact on global health because of the high 
number of infected patients, the ability to successfully transmit itself through sexual 




Two distinct types of the virus are known, herpes simplex virus type-1 (HSV-
1) and herpes simplex virus type-2 (HSV-2).  So far there is no complete cure for HSV 
infections i.e. once infected the patient has it for life. 
  
This study particularly focuses on HSV-1 as it is known to cause infections of 
the skin and mouth which are known as cold sores or fever blisters. 
 
4.1.2 HSV-1 Structure and replication 
 
HSV-1 is a typical herpes virus consisting of a double stranded DNA 
constituting an electron dense core with the icosahedral nucleocapsid built up by 162 
capsomers. The nucleocapsid is surrounded by the adherent tegument, which in turn is 
tightly connected to the envelope. This complete particle is known as the virion (Fig 
4.1). To initiate infection, free virus particles enter the cells through direct fusion of 
the viral and cellular membranes, and the naked nucleocapsid are transported to the 
nucleopores by the microtubular pathways of the cytoskeleton.  The nucleocapsid 
release their linear DNA content into the nucleus and transcription occurs after 
circularization of the DNA. After synthesis and assembly in the nucleus, nucleocapsid 
are temporarily enveloped by the inner nuclear membrane into perinuclear space 
through budding. The enveloped particle is de-enveloped while passing through the 
outer nuclear membrane. The virus then is released via the exocytotic pathway or by 




F ig 4.1 Structural components of Herpes Simplex V i rus-1. 
 
 
4.1.3 Diagnosis and treatment of HSV-1 infection. 
Histochemistry studies are performed from infected cells obtained from the 
base of the lesion (called a Tzank smear). Herpes virus infected cells can fuse at 
neutral pH forming syncytia which can be seen as multinucleated giant cells. 
Immunofluorescence test and in situ hybridization can also be used for detection 
purposes. 
  
Characteristic cytopathic effects (plaque) can be observed from virus samples 





Numerous nucleoside analogue drugs are used to treat herpes infections. These 
drugs are highly specific. The drug is activated in herpes-infected cells (because only 
infected cells express viral thymidine kinase) and hence these drugs show limited side 
effects. 
The most commonly used drugs are the nucleoside analogs acyclovir, 
famciclovir and valacyclovir. But continuous use of these drugs has lead to the 
emergence of resistant herpes mutants. The most common drawback of all these drugs 
is that they are effective only against replicating viruses and not the latent virus.  
 
4.1.4 HSV-1 and drug resistance 
 
Acyclovir (ACV) has been the drug of choice for treatment of HSV-1 
infections for more than a decade. ACV is a nucleoside analogue and it can 
specifically inhibit the replication of HSV-1 infected cells. Early studies have shown 
that on intravenous (IV) administration of ACV to placebo (5 mg/kg every 8 hours for 
5 days), ACV  reduced the duration of viral shedding,  helped heal the lesions faster, 
prevents the development of new lesions, and eases the pain in a shorter period of 
time. But HSV-1 infected host cells treated with ACV in vitro lead to the emergence 
of resistant HSV-1 strains after multiple passages (Larder et al., 1984) raising 
concerns that the same effect may be observed in clinical use of ACV. A study 
conducted in England showed that 0.1-0.6% of HSV isolated from immunocompetent 
hosts were resistant to ACV treatment. It also showed that 6% of 
immunocompromised patients who had received antiviral therapy previously harbor 
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isolates which were resistant. An in vitro study conducted in the United States showed 
that 4.7% of immunocompromised and 0% of immunocompetent hosts infected with 
HSV were resistant to ACV (Pielop et al., 2000). Other drugs have replaced ACV due 
to increase in cases of resistance among patients. Some of these antiviral drugs are 
intravenous foscarnet, this drug functions independent of the HSV-encoded TK to be 
functional.  This is the only FDA approved treatment for immuno-compromised 
patients with HSV. 
 
The most important property of HSV-1 or for that matter any virus is that they 
are obligate intracellular parasites. This property of viruses makes it difficult to design 
drugs targeting specifically against virus without affecting the host cells. The antiviral 
drug targets are mostly based upon the type of the virus, the mechanism by which a 
viral infection is established etc. 
  
The in-depth study of the proteins present in sweat (Table 2.1) revealed the 
presence of the protein Cystatin A in healthy human sweat. It was also observed that 
Cystatin A was one of the abundant proteins present in sweat. Interestingly, Cystatin C 
has been reported to have antiviral activity against HSV (Bjorck et al., 1990). Hence it 
was decided to test whether Cystatin A that was identified in healthy human sweat 










Cystatin superfamily comprises of cysteine proteinase inhibitors which are 
ubiquitous in the body and are generally tight-binding inhibitors of papain-like 
cysteine proteinases, such as cathepsins B, H, L, S, and K. These inhibitors function to 
protect the host tissues from the destructive cysteine proteinases of host, bacterial and 
viral origin which may cause tissue damage due to uncontrolled proteolysis (Libuse A 
et al., 1992). Cystatins are also reported to be involved in the proteolytic processing of 
pheromones and pro-enzymes. The proteins in this family comprise of simple 
sequences of about 100 amino acids to slightly larger molecules with disulfide-bonds 
to much more complex plasma proteins with multiple disulfide bonds and 
carbohydrate groups (Barrett et al., 1987).  
 
4.1.6 Types of Cystatins 
 
'LIIHUHQW&\VWDWLQVFDQEHJURXSHGLQWKUHHPDMRUSURWHLQIDPLOLHVRU³W\SHV´
The grouping of Cystatins into types is based on the sequence similarities with 
homologues. 
 
A) Type 1 Cystatins 
 
The type 1 Cystatins are intracellular Cystatins and are mostly present in the 
cytosol, but are also found in body fluids at considerable concentrations. There are 
two human representatives Cystatin A and B which fall into this group. Cystatin A has 
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been shown to eliminate the proteolytic activity of mite cysteine proteases (Der p 1 
and Der f 1) (Kato et al., 2005). 
 
B) Type 2 Cystatins 
 
The type 2 Cystatins are mainly extracellular, secreted protein and are 
synthesized with 19-28 residue signal peptides, leading to the transport of the mature 
protein across the cell membrane into the extracellular space. Cystatin C, D, S, SN, 
SA,E/M and F form type 2 Cystatins. Cystatin C has been shown to have antiviral 
properties against HSV-1 specifically the replication of HSV-1 suggesting the use of 
such antiviral agents by inhibiting proteinases required for viral replication (Bjorck et 
al., 1990).  
 
C) Type 3 Cystatins 
 
These are multidomain proteins. The mammalian Cystatins belonging to this 
type are the kininogens, which were first described as kinin precursor proteins. These 
proteins are high-molecular-mass Cystatins (60-120kDa) presenting three tandemly 
repeated type 2-like Cystatin domains, with a total of eight disulphide bridges. 
 
4.1.7 Lactofer rin 
 
Lactoferrin (Lf) is an iron binding glycoprotein belonging to the transferrin family. 
It was first isolated in bovine and then from human milk.  It has been further shown 
that lactoferrin is present in exocrine secretions such as milk, tears, nasal exudate, 
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saliva, bronchial mucus, gastrointestinal fluids, cervico±vaginal mucus and seminal 
fluid (Dominique et al., 2004). 
 
Studies into the identification of proteins present in sweat have shown that 
lactoferrin is also present in human sweat (Table 2.1). Additionally, Lactoferrin is 
found in secondary specific granules of circulating polymorphonuclear neutrophils 
(PMNs). Lactoferrin is 673 amino acid long and has a molecular weight of 78-80 kDa 
depending on the number of glycosyl side chains. 
 
Antimicrobial and anti-inflammatory activity studies in vitro have shown that 
lactoferrin is an important host defense protein against infection and excessive 
inflammation. Lactoferrin mostly functions by sequestering iron and/or by interacting 
with other ligands such as those of microbial cell wall components and cellular 
receptors. This interaction with ligands is achieved by the presence of a positively 
charged N-terminus. It has been suggested that Lactoferrin is involved in metabolism 
of iron, prevention of diseases, and alteration of inflammatory and immune responses. 
Hence proving that, the diverse biological functions of lactoferrin still remains elusive.  











F ig 4.2 Sequence homology between Cystatin families  
 
Residues in the surface binding papain-like cysteine proteases are highlighted in blue. Cys residues marked yellow, form two disulf ide bridges in 
type 2 and 3 cystatins. Two extra Cys residues likely forming a third disulf ide bridge in cystatin F are marked green. N-glycosylation sites in the 
cystatin E/M and F sequences are marked in magenta. Atypical insertions in cystatins E/M and F are coloured red. The Asn39 residue, involved 
in tight-binding inhibition of mammalian legumain is marked in orange, in the three cystatins displaying this additional activity as family C13 
inhibitors). The numbering refers to the cystatin C sequence, starting from the f irst residue of the mature protein. For the other cystatins, the 
naturally occurring forms with longest N-terminal segments are shown. Dots indicate gaps introduced to optimize the alignment (Alvarez-
Fernandez et al., 1999).
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4.1.8 Objectives of this study 
 
As mentioned previously, studies have shown that the current drugs available 
for treatment of HSV-1 infections are no longer effective due to increased resistance 
to these drugs by HSV. Thus proving that, there is an urgent need for new drugs for 
treatment of HSV-1. It is also important to note that these drugs should cause minimal 
or no damage to the host cells. This study was aimed towards identifying and studying 
the presence of antiviral proteins in sweat. This would aid in the identification of 
novel, naturally occurring therapeutic targets for HSV-1 treatment. Since Cystatin C 
has been previously shown to have antiviral activity, thus it was hypothesized that 
Cystatin A present in sweat could have a possible antiviral activity against HSV-1. It 
was also decided to test if lactoferrin apart from having antimicrobial activity (as 
shown in Fig 3.10) also has an antiviral function.   
 
4.2 M ater ials and M ethods  
 
4.2.1 Preparation of HSV-1 lysate 
 
The keratinocyte HaCaT cells were grown to 80-90% confluence.  The spent 
PHGLXPZDVUHPRYHGDQGZDVUHSODFHGZLWKIUHVK'0(0)&6ȝORI+69-
1 viral stock (ATCC VR-733) was added and the flask was incubated at 370C and 5% 
CO2 incubator.  The culture flask was observed every 24 hrs for cytopathic effects 
(CPE). After four days (i.e. when maximum CPE was observed) the media was 
removed and was centrifuged at 100RPM for 10 minutes at room temperature. The 
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VXSHUQDWDQWZDV SDVVHG WKURXJK D ȝ ILOter (Millipore). The filtrate containing the 
viral lysate was aliquoted and stored at -800C till further use. 
 
4.2.2 Plaque Assay 
 
The quantification of infectious viral particles was achieved by a standard 
SODTXHDVVD\7KHYLUDOO\VDWHZDVVHULDOGLOXWHGXVLQJSODLQ'0(0PHGLDDQGȝORI
each of the dilution was added to a 24 well plate containing confluent HaCaT cells in 
triplicates. The cells were washed once with plain DMEM. The cells and the virus 
were incubated at 370C and 5% CO2 incubator for 1 hour. After 1 hour the virus was 
removed and the cells were overlaid with 300ȝO plain DMEM media and incubated at 
370C and 5% CO2 incubator for 3 days. Plaques that were seen as a zone of clearance 
were counted in each well and the PFU was determined as follows: 
                            
 
 
  PFU =      number of plaques X dilution factor 
                                          _________________________________ 
 
                                                                    Volume of innocula 
 
 
4.2.3 Cytotoxicity assay 
 
 
The lyophilized and solubilised sweat sample and the recombinant sweat 
proteins were tested for its cytotoxicity against the HaCat cells as described in Dodson 
et al., 2004 with some minor modification. HaCaT cells were grown in 96 well flat 
bottom cell culture plate (Nunc, USA) at density of 105cells/well. The cells were 
allowed to attach and grow for 18 hours at 370C and 5% CO2 incubator.  After 18 
hours, the spent media was removed and the cells were washed once with plain 
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DMEM media. The cells were then treated with varying amounts of the solubilised 
sweat proteins and then incubated at 370C and 5% CO2 incubator for three days. After 
three days, the plate was centrifuged at 1000 rpm for 10 minutes and 20ȝO of  CellTiter 
96® AQueous One Solution Cell Proliferation Assay (MTS) kit reagent (Promega) was 
added to each well. The plate was further incubated at 370C and 5% CO2 incubator for 
2 hours after which the plate was read at 490 nm. The assay was done in triplicates. 
 
 




HaCaT cells were grown in 96 well flat bottom cell culture plate at density of 
105 cells/well. The cells were allowed to attach and grow for 18 hours at 370C and 5% 
CO2 incubator.  After 18 hours, the spent media was removed and the cells were 
washed once with plain DMEM media. The cells were then treated with varying 
amounts of the solubilised sweat proteins/recombinant sweat proteins and infected 
with HSV-1 (MOI =0.067 PFU/ml).  The cells were then incubated at 370C and 5% 
CO2 incubator for three days. After three days, the plate was centrifuged at 1000 rpm 
for 10 minutes and 20ȝO of  CellTiter 96® AQueous One Solution Cell Proliferation 
Assay (MTS) kit reagent (Promega) was added to each well. The plate was further 
incubated at 370C and 5% CO2 incubator for 2 hours after which the plate was read at 
490 nm. 
 
4.2.5 Plaque Reduction Assay 
 
The HaCaT cells were grown to confluence in a 24 well plate. The cells were 
washed once with plain DMEM media followed by the addition of varying 
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concentrations of solubilised sweat proteins/recombinant proteins and diluted HSV-1 
virus suspension (containing approximately 150PFU).  The plate was then incubated 
at 370C and 5% CO2 incubator for 2 hours and then the cells were overlaid with 300ȝO 
of plain DMEM media and further incubated at 370C and 5% CO2 incubator for 3 
days. The plaques formed were counted on the third day. 
 
4.2.6 Mode of action of Cystatin A and Lactofer rin on HSV-1 
 
A) A ttachment assay- To study the effect of Cystatin A and Lactoferrin on 
the attachment of HSV-1 on HaCaT cells, the following assay was performed 
The HaCaT cells were grown to confluence in a 24 well plate.  Once the confluence 
was reached the spent media was removed and the cells were washed once with plain 
DMEM media. The cells were then infected with diluted HSV-1 virus suspension 
(approximately 150PFU) in the presence or absence of test proteins and incubated for 
1 hour at 40C.  Cells were then washed with phosphate-buffered saline (PBS) thrice to 
remove proteins and unattached virus, overlaid with ȝl plain DMEM medium, and 
incubated at 37°C, 5% CO2 incubator for 3 days. The plaques were counted on the 
third day. 
 
B) Entry assay: To study the effect of Cystatin A and Lactoferrin on the entry 
of HSV-1 into HaCaT cells, the following assay was performed. The HaCaT cells 
were grown to confluence in a 24 well plate.  Once the confluence was reached the 
spent media was removed and the cells were washed once with plain DMEM media. 
The cells were then infected with diluted HSV-1 virus suspension (approximately 
150PFU) incubated for 1 hour at 40C to allow the virus to attach to the cells. Cells 
were then washed with phosphate-buffered saline (PBS) thrice to remove unattached 
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virus. Varying concentrations of the test proteins were added to respective wells and 
the plate was transferred to 37°C incubator for 1 hour. To inactivate extracellular virus 
and remove any proteins, 1 ml of acidic glycine was added to each cell monolayer and 
treated for 20 seconds at room temperature. Cells were later washed with plain 
medium three times to return the pH to neutral, overlaid  with ȝO of plain DMEM 
media and incubated at 370C and 5% CO2 incubator for 3 days. The plaques formed 
were counted on the third day. 
 
C) Antireplicative assay: To study the effect of Cystatin A and Lactoferrin on 
the replication of HSV-1 on HaCaT cells, the following assay was performed 
The HaCaT cells were grown to confluence in a 24 well plate.  Once the confluence 
was reached the spent media was removed and the cells were washed once with plain 
DMEM once. The cells were then infected with diluted HSV-1 virus suspension 
(approximately 150PFU) incubated for 1 hour at 40C to allow the virus to attach to the 
cells. After 1 hour the infected cells were shifted to an incubator set at 370C for 
another one hour.  This incubation time ensured that the virus could attach and enter 
the HaCaT cells. The cells were then washed with phosphate-buffered saline (PBS) 
three times to remove any extracellular virus. The cells were then overlaid with plain 
media containing varying concentrations of test proteins and incubated at 370C and 
5% CO2 incubator for 3 days. The plaques formed were counted on the third day. 
 
D) Y ield reduction assay: The HaCaT cells were grown to confluence in a 24 
well plate.  Once the confluence was reached the spent media was removed and the 
cells were washed once with plain DMEM once. The cells were then infected with 
diluted HSV-1 virus suspension (approximately 150PFU) incubated for 1 hour at 40C 
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to allow the virus to attach to the cells. After 1 hour the infected cells were shifted to 
an incubator set at 370C for another one hour.  This incubation time ensured that the 
virus could attach and enter the HaCaT cells. The cells were then washed with 
phosphate-buffered saline (PBS) three times to remove any extracellular virus. The 
cells were then overlaid with plain media containing varying concentrations of test 
proteins and incubated at 370C and 5% CO2 incubator for 3 days.  After three days the 
media contents from each well were transferred into respectively labeled eppendorf 
tubes.  A plaque assay was performed using these lysate to determine the viral PFU 
counts in order to determine the yield. 
 
E) Egress or release assay: To study the effect of Cystatin A and Lactoferrin 
on the release of HSV-1 from infected HaCaT cells, the following assay was 
performed. The HaCaT cells were grown to confluence in a 24 well plate.  Once the 
confluence was reached the spent media was removed and the cells were washed once 
with plain DMEM once. The cells were then infected with diluted HSV-1 virus 
suspension (approximately 150PFU) incubated for 1 hour at 40C to allow the virus to 
attach to the cells. After 1 hour the infected cells were shifted to an incubator set at 
370C for another one hour.  This incubation time ensured that the virus could attach 
and enter the HaCaT cells. The cells were then washed with phosphate-buffered saline 
(PBS) three times to remove any extracellular virus. The cells were then overlaid with 
plain media containing varying concentrations of test proteins and incubated at 370C 
and 5% CO2 incubator. The medium contents from each of the wells were removed 
and 500ȝO of phosphate-buffered saline (PBS) was added to the wells. The entire plate 
was then freeze-thawed (freeze at -800C and thawed at 370C) thrice to release the 
intracellular viruses. The lysate thus obtained was collected and the PFU count of the 
84 
 
same was determined by Plaque assay. This procedure was performed on 24 hours and 
48 hours. 
 
4.3 Results and Discussions 
 
4.3.1 Antiviral activity of solubilised sweat proteins by cell p roliferation assay 
 
An antiviral assay was done using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS) kit reagent (Promega). This assay calorimetrically 
determines the number of viable host cells in the well. The quantity of formazan 
product formed is measured at 490nm absorbance which is directly proportional to the 
number of living HaCaT cells in the well. This assay was done as a preliminary step to 
test whether healthy human sweat harbors any proteins which have an inhibitory 
and/or killing effect on HSV-1.   
 
As seen from the Fig 4.3, it can be clearly noted that on infection of the HaCaT 
cells with virus leads to death and hence decreased viability. This decrease in the 
viability of cells can be seen as a marked reduction in the percentage cell survival as 





F ig 4.3 Antiviral activity of solubilised sweat proteins against HSV-1 virus 
determined by cell p roliferation assay . HaCaT cells were grown in a 96 well plate 
followed by addition of Sweat proteins and further infected with HSV-1. The 
percentage of viable HaCaT cells was later determined by the addition of MTS 
reagent. 
 
 Interestingly, the cells that were infected with virus and were also treated with 
solubilised sweat proteins at different doses showed that as the concentration of sweat 
proteins added into the wells increases the percentage of  viable cells also increases. 
This shows that the protein components in sweat have antiviral effect against HSV-1. 
Due to this antiviral effect of sweat proteins the virus HSV-1 is unable to infect and 
kill the cells thus increasing the viability of the cells. 
 
4.3.2 Plaque Reduction Assay 
 
A plaque assay involves growing a monolayer of host cells onto a tissue 
culture plate and then adding a diluted mixture of virus suspension onto the 
monolayer. On providing sufficient incubation time, the viruses will infect the cells by 
first attaching to the host cells via cell surface receptors. The next step is the entry of 
the viral nucleic acid into the host cell cytoplasm followed by intra-cellular 
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replication. Once the virus begins to replicate intra-cellularly numerous virus particles 
are produced inside the cells. The cells then burst, leading to the release of the newly 
replicated viruses. These newly replicated viruses released from previously infected 
cells continue to infect neighboring host cells. This process leads to the formation of 
zones of clearance (caused due to the killing of cells) on the monolayer. These zones 
of clearance are called plaques. The number of plaques is counted which gives us an 
estimate of the number of infectious viruses.  Thus a plaque assay is an important 
assay to determine the number of infectious virus. 
 
In this study, a plaque reduction assay was performed to check if in the 
presence of sweat proteins, the number of plaques formed by the virus is reduced as 
compared to that in the absence of sweat proteins.  
 
Confluent monolayer of HaCaT cells were infected with a diluted suspension 
of HSV-1 in the presence/absence of sweat proteins. The plaque count was determined 
to assess the effect of the sweat proteins on the plaque formation. Fig 4.4 clearly 
shows that as the concentration of solubilised sweat proteins is increased the number 
of plaques formed as compared to that of cells that were not treated with sweat 
proteins decreases. This further shows that human sweat indeed has proteins that 





F ig 4.4 E ffect of varying concentrations of lyophilized sweat proteins on HSV-1 
plaque formation using HaCa T cells as host cells. HaCaT cells were treated with 





4.3.3 Screening of recombinant candidate sweat proteins for antiviral activity 
 
In an effort to further characterize and study the proteins with antiviral 
function, a selected few candidate proteins were cloned and expressed. The candidate 
proteins chosen for the antiviral study were those that had shown antibacterial activity 
in the previous study. These candidate proteins were expressed and purified and tested 
individually at a concentration of 0.6mg/ml for antiviral activity using the CellTiter 
96® AQueous One Solution Cell Proliferation Assay (MTS) kit reagent (Promega). Fig 
4.5 clearly shows that cells treated with the recombinant proteins Lactoferrin and 
Cystatin A showed increased viability of host cells as compared to those treated with 
Psoriasin and SOD1. This proves that both the proteins Cystatin A and Lactoferrin 





F ig 4.5 Screening of candidate recombinant sweat proteins for antiviral activity 
against HSV-1 using cell p roliferation assay. HaCaT cells were grown in a 96 well 
plate and later treated with recombinant proteins  in the presence of HSV-1. The cell 
survival of HaCaT cells in the presence of Cystatin A was determined by MTS 
reagent. 
 
4.3.4 Cytotoxicity of recombinant candidate sweat proteins 
 
Preliminary antiviral studies by cell proliferation assay showed that two of the 
proteins present in healthy human sweat ±Cystatin A and Lactoferrin have antiviral 
effect against HSV-1 (Fig 4.5).  Hence it was decided to pursue in-depth studies for 
these proteins with respect to antiviral function. But before proceeding further towards 
understanding the antiviral activity, the test proteins were analyzed for cytotoxicity on 
HaCaT cells. 
 
Cytotoxicity studies for the test proteins- Cystatin A and Lactoferrin on HaCaT 
cells was performed to ensure that the dose used for further assays are not lethal to the 
growth and proliferation of HaCaT cells. Proliferation study using MTS reagent 
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showed that the test proteins Cystatin A and Lactoferrin did not have any cytotoxic 
effect on the HaCaT cells Fig 4.6 and Fig 4.7.  
 
 
F ig 4.6 Cytotoxicity profile of Cystatin A on HaCaT cells determined by cell 
proliferation assay. HaCaT cells were treated with a range of different concentrations 
of Cystatin A. The metabolically active cells remaining in each well was determined 




F ig  4.7 Cytotoxicity profi le of Lactofer rin on HaCaT cells determined by cel l 
proliferation assay. HaCaT cells were treated with a range of different concentrations 
of Lactoferrin. The metabolically active cells remaining in each well was determined 





4.3.5 Plaque reduction assay for Cystatin A and Lactofer rin 
 
To further validate the antiviral activity of Cystatin A and Lactoferrin, a plaque 
reduction assay was carried out. This assay aimed to study the effect of the test 
proteins on the number of plaques formed and compare it to the number of plaques 
formed in the absence of the two test proteins. 
 
F ig 4.8 Effect of varying concent ration of Cystatin A on HSV-1 plaque formation 
using HaCaT host cells. HaCaT cells were treated with Cystatin A followed by the 
addition of diluted HSV-1 virus. The plaques formed were counted after 72 hours and 
represented as percentage plaques formed.  
 
 
The results for the plaque reduction assay in the presence of Cystatin A and 
Lactoferrin showed that both these proteins reduced the number of plaques formed as 
compared to that of the cells that were infected with virus in the absence of the 
proteins. These proteins also showed a dose dependent reduction in the number of 






F ig 4.9 Effect of varying concent ration of Lactofer rin on HSV-1 plaque 
formation using HaCaT host cells. HaCaT cells were treated with Lactoferrin 
followed by the addition of diluted HSV-1 virus. The plaques formed were counted 





4.3.6 Mode of action 
 
 In this study, it has been established so far that the sweat proteins Cystatin A 
and Lactoferrin both have an antiviral effect on HSV-1 infection in vitro. Cystatin A 
and Lactoferrin show a 30% reduction in the plaque formation as compared to the 
control (Fig 4.8 and Fig 4.9) at a concentration of 1.38nM and 3.99 nM respectively. 
 
 The next step was to specifically identify the stage of HSV-1 life cycle 
that these proteins affects which leads to the decreased formation of plaques and hence 
increased survival of the host cells.   
 
As mentioned previously, the life cycle of HSV-1 is comprised of three major 
stages-1) attachment of the virus to the host cells, 2) entry and 3) intracellular 
replication. So experiments were designed such that the proteins Cystatin A and 
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Lactoferrin each were introduced into the assay at specific stages of the HSV-1 life i.e. 
during the attachment phase, entry phase and the replication phase to determine the 
effect of the test proteins on the plaque counts. The plaque counts thus obtained were 
later compared to those that were observed in the absence of the test proteins.  
 
On studying the effect of Cystatin A on the attachment and entry of the virus 
into the host cells by Plaque reduction assay, it was observed that the number of 
plaques formed when Cystatin A was introduced into the wells at the time of 
attachment of HSV-1 onto HaCaT cells reduced the number of plaques formed in a 
dose dependent manner (Fig 4.10). While addition of Cystatin A during the entry of 
the virus had no effect on the number of plaques formed as compared to the control 
(Fig 4.11) Thus proving that, Cystatin A inhibits the attachment of the HSV-1 virus 
onto the host cells. 
 
A) Cystatin A  
 
F ig 4.10 Effect of varying concentration of Cystatin A on the attachment of HSV -
1 onto HaCaT cells. Confluent monolayer of HaCaT cells was infected with HSV-1 
in the presence of Cystatin A followed by incubation for 1hour at 40C, followed by 
washing with PBS. The plaques were allowed to form by incubation at 37°C, 5% CO2 






F ig 4.11 Effect of varying concent ration of Cystatin A on the entry of HSV-1 into 
HaCaT cells. Confluent monolayer of HaCaT cells was infected with HSV-1for 1 
hour followed by the addition of Cystatin A after washing away the un-attached virus. 
The plate was incubated at 37°C, 5% CO2 incubator for 1 hour. The extracellular virus 
was then incactivated by addition of glycine and incubating for 20 seconds at RT 
followed by washing with plain DMEM media. Cells were overlayed with plain 
DMEM followed by incubation at at 37°C, 5% CO2 incubator.  The plaques were 




F ig 4.12 Effect of varying concent ration of Cystatin A on the replication of HSV-
1 in HaCaT cells. Confluent monolayer of HaCaT cells was infected with HSV-1for 1 
hour at 40C followed by another1 hour incubation at 370C. The cells were washed with 
PBS and then overlaid with plain media containing varying concentrations of Cystatin 
A and incubated at 370C and 5% CO2 incubator. The plaques formed were counted 






F ig 4.13 Effect of Cystatin A on the viral yie ld obtained by determining the PF U 
count in the cell culture supernatants of infected HaCaT cells overlaid with 
Cystatin A . The supernatants obtained from replication assay was collected and used 
as lysate to re-infect freshly grown confluent HaCaT monolayer cells and the plaque 
count was determined after 72 hours. 
 
 
To study the effect of Cystatin A on the replication of the virus, the protein 
was added after the virus had attached and entered the host cells. Analysis of the 
number of plaques formed showed a dose dependent decrease in the number of 
plaques formed (Fig 4.12).  To further confirm this study, a yield reduction assay was 
done. This assay was carried out to ensure that a decrease in the intracellular 
replication also leads to a decrease in the number of viruses released from the cells. 
Hence the supernatants of the intracellular replication assay were removed and each of 
the supernatants were used as a lysate and inoculated into fresh HaCaT monolayer and 
the number of plaques so formed was studied. This assay showed that there was dose 
dependent decrease in the number of plaques formed (Fig 4.13). These results 
suggested that the protein Cystatin A not only affected the attachment of the virus but 




While the studies done so far suggested that Cystatin A affected the attachment 
and intracellular replication of HSV-1, before a final conclusion could be made it was 
necessary to check if the protein Cystatin A had any effect on the release of the virus 
from the infected HaCaT cell. For this, the host cells were lysed after 24 and 48 hours 
of infection and then the lysate thus obtained was used to infect fresh HaCaT 
monolayer and the plaque count thus obtained was documented. This study showed us 
whether there was an actual decrease in the intracellular count of the virus. The plaque 
count thus obtained showed that the virus replicated successfully inside the host cells 
which could be concluded because there was no decrease in the plaque count when 
compared to the controls from the lysate obtained after 24 and 48 hours of infection 
(Fig 4.14).  This suggested that the protein Cystatin A had no effect on the 
intracellular count of the virus.  
 
 
F ig 4.14 Int racellular vi ral count determined by cell lyses of the infected HaCa T 
cells at varying time period. Confluent monolayer of HaCaT cells was infected with 
HSV-1for 1 hour at 40C followed by another1 hour incubation at 370C. The cells were 
washed with PBS and then overlaid with plain media containing varying 
concentrations of Cystatin A and incubated at 370C and 5% CO2 incubator. After 24 
and 48 hour post infection the host cells were lysed to release the intracellular virus. 
The lysate thus obtained was collected and the PFU count of the same was determined 




On comparing the results obtained from replication and yield reduction assay 
(Fig 4.12 and 4.13) and the intracellular count assay (Fig 4.14) it can be concluded 
that Cystatin A has no effect on the replication of the virus as there is no decrease in  
the number of plaques formed. The decrease in the plaque count observed in 
replication and yield reduction assay (Fig 4.12 and 4.13) was probably a result of the 
inhibitory activity of Cystatin A on the release of the virus from HaCaT cells. This 
explains the decrease in the number of plaques formed in replication assay, because 
for the viruses to form plaques it is required that the viruses are released from the cells 
and the viruses thus released infect neighboring cells leading to the formation of 
plaques. A decrease in the number of plaques formed and also a decrease in the yield 
of the virus while there is no decrease in the intracellular replication count of the virus 
suggests that though HSV-1 could replicate successfully in the presence of Cystatin A, 
but the virus was unable to release itself from the HaCaT cells, and hence was 
incapable of producing plaques as compared to the controls.  Thus it can be concluded 
that the mode of action of the antiviral protein Cystatin A is probably inhibition of 
attachment and release of the virus. 
 
B) Lactofer rin 
 
Studies carried out to determine the mode of action of Cystatin A was repeated 
for Lactoferrin, and it was observed that  lactoferrin had no effect on the attachment 






F ig 4.15 Effect of varying concentration of Lactofer rin on the attachment of 
HSV-1 onto HaCaT cells. Confluent monolayer of HaCaT cells were infected with 
HSV-1 in the presence of Lactoferrin followed by incubation for 1hour at 40C, 
followed by washing with PBS. The plaques were allowed to form by incubation at 
37°C, 5% CO2 incubator.  The plaques were counted after 72 hours. 
 
 
F ig 4.16 E ffect of varying concentration of Lactofer rin on the entry of HSV-1 
into HaCaT cells. Confluent monolayer of HaCaT cells were infected with HSV-1for 
1 hour followed by the addition of Lactoferrin after washing away the un-attached 
virus. The plate was incubated at 37°C, 5% CO2 incubator for 1 hour. The 
extracellular virus was then inactivated by addition of glycine and incubating for 20 
seconds at RT followed by washing with plain DMEM media. Cells were overlayed 
with plain DMEM followed by incubation at at 37°C, 5% CO2 incubator. The plaques 
were counted after 72 hours. 
 
A replication and yield reduction assay studies showed that there was a dose 






F ig 4.17 Effect of varying concent ration of Lactofer rin on the replication of HSV-
1 in HaCaT cells.  Confluent monolayer of HaCaT cells were infected with HSV-1for 
1 hour at 40C followed by another1 hour incubation at 370C. The cells were washed 
with PBS and then overlaid with plain media containing varying concentrations of 
Lactoferrin and incubated at 370C and 5% CO2 incubator. The plaques were counted 





F ig 4.18 Effect of  Lactofer rin on the viral yield obtained by determining the PF U 
count in the cell culture supernatants of infected H aCaT cells overlaid with 
Lactofer rin. The supernatants obtained from replication assay was collected and used 
as lysate to re-infect freshly grown confluent HaCaT monolayer cells and the plaque 
count was determined after 72 hours.  
 
As mentioned previously, a reduced plaque count obtained by performing a 
replication assay and yield reduction assay may not necessarily imply that the 
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candidate protein is an anti-replication protein. This is because, a decreased plaque 
count will be observed if the protein inhibits the release of the newly replicated virus 
into the media which in turn may lead to a decreased plaque count. Thus it is 
important to determine whether the virus is able to replicate inside the host cells in the 
presence of the protein. For this, the host cells were lysed at regular intervals i.e. after 
24 and 48 hours after infection in the presence /absence of the test protein. The lysate 
thus obtained was used to infect fresh HaCaT monolayer cells. This study showed that 
the intracellular viral count after 24 an 48 hours of infection decreased with an 
increase in the concentration of the lactoferrin protein (Fig 4.19). 
 
Comparing the results obtained from the intracellular viral count assay (Fig 
4.19) and the results obtained from the replication and yield reduction assay (Fig 4.17 
and 4.18) it can be clearly seen that a decrease in the plaque count for replication and 
yield reduction assay was due to the decrease in the intracellular replication of HSV-1 
inside the host cells. 
 
This clearly shows that lactoferrin inhibits the intracellular replication of the 
virus HSV-1. Hence, it can be concluded that the probable mode of action of the 







F ig 4.19 Int racellular vi ral count determined by cell lyses of the infected HaCa T 
cells at varying time period . Confluent monolayer of HaCaT cells were infected with 
HSV-1for 1 hour at 40C followed by another1 hour incubation at 370C. The cells were 
washed with PBS and then overlaid with plain media containing varying 
concentrations of Lactoferrin and incubated at 370C and 5% CO2 incubator. After 24  
and 48 hours post infection the cells were lysed to release the intracellular virus. The 






4.4 Conclusions  
 
Herpes Simplex Virus -1 (HSV-1) infection is a common and ubiquitous 
infection. Up to 80-90% adults may have serological evidence of this infection. 
Herpes labialis (cold sores), which is the most common presentation of chronic HSV-1 
infection, occurs in approximately 20±40%of the general population (Hull et al., 
2007). Recurrent Herpes labialis infections are generally mild but they are generally 
uncomfortable and cosmetically unpleasing. Patients suffering from Herpes labialis 
also show Erythema multiforme (EM) lesions. Erythema multiforme (EM) is an acute, 
self-limiting, usually symmetrical cutaneous eruption characterized by the 
development of dusky erythematous macules, occurring mostly in the hands, forearms 
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and oral mucosa. HSV-1 is able to ascend through sensory nerve axons to establish 
chronic, life-long, latent infections. 
 
Viral infections are considered to be one of the most alarming conditions in 
health care as it causes complex illness. Development of an antiviral drug is one of the 
most challenging tasks because most viruses are obligate intracellular parasites. These 
viruses depend on the host metabolism for their replication. Hence development of 
antiviral drugs poses a serious challenge as these drugs could also affect host cells.  
 
As mentioned previously, the identification and introduction of antiviral drugs 
in the market faces a lot of challenges. These challenges are mainly due to the inherent 
properties of viruses. Unlike bacteria, viruses do not have a wide variety of 
mechanisms to develop resistance to chemotherapeutic agents. They are genetically 
simple and metabolically inert. However viruses, do have two properties to evade 
potential inhibitors, firstly, they are capable of replicating to high titers inside host 
cells and secondly their ability to mutate rapidly. The other complication that arises 
with treatment of HSV-1 is their ability to become latent viruses inside host cells. 
Most of the drugs available are active against actively proliferating viruses. It is 
commonly observed that treatment with Acyclovir does not prevent future 
recurrences. It is also important to note that the drugs used for antiviral therapy do not 
cause harmful immunosuppressive effects on the host cells. As discussed previously, 
most of the drugs used in antiviral therapy are anti-proliferative, and inhibition of host 
immune cells has been a constant concern in antiviral therapy. Apart from this the cost 
of these drugs also hampers the successful treatment of HSV-1 infections in many 
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third world countries. Hence proving that, there is an urgent need for safer and more 
economical therapy for treatment of HSV-1 infections. 
 
The main objective of this study was to indentify the presence of any antiviral 
proteins present in human sweat against HSV-1. For which, pooled and concentrated 
human sweat was used to test if the sweat had any antiviral proteins. Once the 
presence of antiviral proteins in sweat was established, candidate recombinant proteins 
were expressed and purified and each of these were tested against HSV-1 using the 
cell proliferation assay. These efforts lead to the identification of two novel antiviral 
proteins Cystatin A and Lactoferrin. Since the major concern in any antiviral therapy 
is the effect of the drug on host cells, these proteins were tested for cytotoxicity. Once 
it was ensured that the proteins showed no cytotoxic effects on the HaCaT cells in 
vitro, the proteins were further tested to ascertain their antiviral property using the 
Plaque reduction assay. Both Cystatin A and Lactoferrin showed marked decrease in 
number of plaques formed and thus an increased host cell survival rate as compared to 
the untreated controls.  Since this study established the antiviral activity of Cystatin A 
and Lactoferrin against HSV-1 in vitro, it becomes crucial to also determine the 
mechanism of action of these proteins on HSV-1. For this, each of the candidate 
proteins was introduced into the assay plate at specific stages of virus life cycle- 
Attachment, Entry and during the replication of the virus inside the host. Interestingly 
Cystatin A was found to inhibit both attachment and replication of the virus. To 
further confirm the inhibitory effect of Cystatin A on the replication of HSV-1, the 
HaCaT cells were lysed 24 and 48 hours post infection with HSV-1, overlaid with 
Cystatin A and the PFU count of the lysate was determined. It was observed that there 
was no difference in the PFU count in treated and untreated cells. Hence it was 
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concluded that possibly Cystatin A inhibits the release of the newly replicated virus 
from the host cells. As mentioned previously, the HSV-1 virion is composed of four 
structural elements: a core which contains the DNA; an icosahedral capsid, which 
encloses the genome; a layer immediately surrounds the capsid called the tegument; 
and an envelope, which encloses the whole structure. The envelope consists of the 
viral glycoproteins embedded on it. The viral tegument that consists of virus-specified 
polypeptides has diverse functions such as transcription activation, shut off host 
protein synthesis, and un-coat the virus genome, and probably many more. Based on 
homology studies it has been shown that corresponding primary and predicted 
secondary structures of UL36 from HSV-1 and M48 from Murine Cytomegalovirus, 
all herpes viruses contain a Ub-specific cysteine protease embedded within the large 
tegument protein (Gredmark et al., 2007). In this study it has been shown that Cystatin 
A has an antiviral effect on HSV-1 virus with respect to the inhibition of the viral 
attachment and egress of the virus. Cystatin A being a cysteine protease inhibitor, it is 
suspected that the anti-attachment and anti-egress could be because of the inhibition of 
the tegument protein cysteine protease which is encoded within the N-terminal 
approximately 500 residues of the UL36 gene product, the largest (3164 aa) tegument 
protein of HSV-1. The exact mechanism by which Cystatin A inhibits this cysteine 
protease at the stages of attachment and egress still remains to be studied in detail. The 
approach undertaken in this study to understand the mechanism of action provides a 
basic platform for further in-depth studies. Further studies involving construction of 
viral mutants with appropriate mutations and/or deletions within the UL36 tegument 





On the other hand lactoferrin clearly showed an inhibitory effect on the 
replication of HSV-1, as the lysate obtained from the lysed host cells showed a 
marked decrease in the PFU count as compared to the untreated controls. While the 
precise mode of this inhibition is still unclear it is well known that lactoferrin is an 
iron binding protein, it is suspected that probably this property plays a major role in its 
antiviral function. 
 
Iron is essential for growth and replication. It serves as a prosthetic group for 
numerous enzymes and proteins involved in electron transfer that are part of the 
energy metabolism pathway. It is also required for the synthesis of 
deoxyribonucleotides for DNA synthesis and repair. Pathogens and host have an 
ambiguous relationship with iron. Hosts maintain an iron restricted environment 
which is essential for the suppression of the cytotoxic activity of iron. The dependence 
of pathogens on the hosts iron supply makes the pathogens susceptible to the 
bacteriostatic effects of iron limitation.  While pathogens adapt to the iron limitation 
environment by production of iron chelating agents etc, virus in contrast have not 
evolved any mechanisms for iron scavenging. DNA viruses like the HSV are directly 
dependent on host iron for proliferation as iron plays an essential role as the catalytic 
center for ribonucleotide reductase. Ribonucleotide reductase (RNR) provides an 
essential step in the formation of DNA precursors by catalyzing the reduction of 
ribonucleoside diphosphates to deoxyribonucleoside diphosphates. Hence Herpes 
virus is dependent on the RR for proliferation; the enzyme is produced during the 
initial stages of the infection so that adequate dNTPs can be produced for viral DNA 
synthesis (Jacobson et al., 1989).  Studies have shown that selective inhibition of RNR 
provides new approaches for antiviral drugs against HSV (Stanislaw et al., 2006).  It is 
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suspected that the inhibition of replication of HSV-1 by lactoferrin shown in this study 
could be because of the iron chelation property of lactoferrin making the milieu iron 
deficient and thus unavailable for the HSV-1 RNR enzymes. This study provides 
initial steps into understanding the mechanism of action of lactoferrin on HSV-1.  
 
This study has successfully identified two novel proteins detected in healthy 
human sweat with antiviral property against HSV-1. The proteins Cystatin A and 
Lactoferrin showed inhibitory effect on HSV-1 in vitro.  Cystatin A was shown to 
affect HSV-1 by inhibiting attachment and release of the virus from host cells while 
Lactoferrin was shown to inhibit replication of the virus inside host cells. The 
understanding of the mechanism of action of these antiviral proteins revealed that both 
these proteins inhibit the HSV-1 at important stages of HSV-1 life cycle. Firstly the 
inhibition of attachment of HSV-1 onto HaCaT cells by Cystatin A shows that 
Cystatin A in sweat plays a vital role in preventing the first step of HSV-1 infection. 
HSV-1 skin infections spread by direct contact, the property of Cystatin A ensures that 
a KHDOWK\LQGLYLGXDOZKRFRPHVLQFRQWDFWZLWKDQLQIHFWHGSHUVRQGRHVQ¶WJHWLQIHFWHG
as the sweat Cystatin A prevents the attachment of the virus shed by infected 
individuals and thus establishment of an infection. Cystatin A not only prevents 
attachment of the virus but also prevents the release of the virus. This property of 
Cystatin A ensures that once the virus gains entry into the cells (via breaks in skin or 
through other routes) the newly replicating virus is contained at the site of infection 
and thus inhibiting the spread of HSV-1 to the neighboring cells, making further 
treatment and recovery speedy and efficient.  Lactoferrin which was shown to have 
anti-replication activity against HSV-1 is vital for reducing and controlling the viral 
titers. As mentioned previously, one of the problems in antiviral treatment is their 
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ability to attain high titers once inside the host cells. The anti- replication property of 
Lactoferrin oppresses the replication of HSV-1 inside the host cells without affecting 
the host cells. The presence of Lactoferrin in sweat ensures that even if the once latent 
virus are reactivated, its replication and hence establishment of recurrent infections 
can be averted. 
 
The identification of the human sweat proteins Cystatin A and Lactoferrin with 
antiviral property against HSV-1 in vitro, opens new avenues in the treatment of HSV-
1 infections, especially skin infection such as Herpes labialis. While the current 
available treatments carry a risk of adverse effects on host cells, these proteins were 
shown to have no cytotoxic effects on host cells in vitro.  As discussed previously, 
there has been reports indicating the increase in cases of resistance of HSV-1 to the 
current available treatments such as Acyclovir, these two sweat proteins can replace 
the chemotherapeutic drugs as they are naturally occurring and hence are thought to 
have no side effects against humans.  
 
This study has aided in the identification of proteins with antiviral activity 
against HSV-1 and hence paving the way for exploring the use of sweat proteins 
Cystatin A and Lactoferrin as targets for HSV-1 therapy.  The presence of these 
proteins in sweat with antiviral property establishes the theory that sweat proteins 







C H APT E R 5: IDE N T I F I C A T I O N O F W O UND R EPA IR 
PR O T E INS IN H U M A N SW E A T . 
5.1 Introduction  
 
5.1.1 Skin wound healing - Overview  
 
 
The primary function of the skin is to serve as a protective barrier against the 
environment. Hence it can be said that an intact healthy skin is of pivotal importance. 
A breach in the skin due to injury or illness could lead to minor disabilities or fatal 
consequences. Skin wound healing is considered to be the most orderly process 
involving multiple pathways. On injury to the skin a series of mediators and processes 
are set to play to restore the intact nature of the skin. The skin injury is temporarily 
repaired by the formation of a clot; then processes to replace the wounded cells of the 
skin begin. The developments in cellular and molecular biology have vastly increased 
our understanding of the biological processes that lead to wound repair and tissue 
regeneration. But the exact process of wound repair still remains unclear.  Wound 
repair is thought to involve the following major steps: 
 
A) Inflammation: An injury to the skin causes disruption of the blood vessels 
which eventually leads to the formation of clot. The formation of a clot forms a 
plug to prevent the entry of any foreign particles or environmental pathogens 
from gaining entry into the system. The clot also provides a base for cell 
migration (Singer A. J. et al., 1999). The injured parenchymal cells also attract 
numerous wound repair mediators at the site of injury. These mediators in turn 
recruit inflammatory leukocytes. 
Infiltrating neutrophils wash out the wounded area of foreign particles 
and bacteria and are then phagocytosed by macrophages. Once activated, the 
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macrophages release a battery of cytokines and growth factors at the wounded 
site, thus amplifying the initial wound signals. 
 
B) Epithelization: Re-epithelization of the wound begins within hours after 
injury. Re-epithelization is the reconstruction of a wound with new epithelium 
and consists of both migration and proliferation of keratinocytes at the 
periphery of the wound. As epidermal migration continues, keratinocytes at the 
wound margin begin to proliferate behind the actively migrating cells. This 
proliferation helps feed the migrating sheets at the wound margins. 
 
C) Formation of granulation tissue: New stroma or granulation tissue begins to 
develop at the site of injury 3-4 days after injury. Numerous new capillaries 
begin to develop at the site followed by a rapid influx of macrophages, blood 
vessels and fibroblasts at the site of the wound. The macrophages function to 
provide a continuous source of growth factors, the fibroblasts produce new 
matrix to support cellular growth while the blood vessels provide oxygen and 
nutrients for the metabolism of the newly growing cells. 
 
The proliferation phase comprises of collagen deposition by fibroblasts at 
the wound bed. This collagen matrix functions to replace the initial fibrin-
fibronectin clot. This fibrin clot supports the growth and differentiation of the 
cells. Once the level of collagen production equals the level of collagen 
degradation leads to the initiation of the re-modeling phase. This causes 




The precise mechanism of wound repair is still trivial even though extensive 
amount of research studies are being currently pursued in the field of wound 
healing and repair. Current studies are concentrated in elucidating the relevant 
cytokines required for wound repair pathways to further understand the molecular 
mechanisms regulating the wound healing process. Research studies directed 
towards molecular modulation of wound healing and novel mediators involved in 
wound repair will prove to be useful in developing therapeutics that could save the 
lives of many.  
 
5.1.2 Sweat and Wound repair 
 
In a quest to identify the proteins present in sweat and the functions of the 
same, we came across a few proteins with possible roles in cutaneous wound healing. 
The 2DE followed by MALDI-TOF/TOF and 2D-LC-MS/MS detected the presence 
of the proteins Calgranulin A (S100 A8) & Calgranulin B (S100A9) and SOD1. An 
in-depth literature study into these proteins revealed a few clues regarding its possible 
role in cutaneous wound healing. 
 
5.1.3 S100 proteins in the epidermis 
 
 
The S100 proteins consist of a family of low molecular weight proteins that are 
involved in multiple functions. The S100 family has derived its name due to its 
property of being 100% soluble in ammonium sulfate solution (Moore et al., 1965). 
Many members of this family of gene are encoded in the epidermal differentiation 
complex (EDC) located on chromosome 1q21 (Volz et al., 1993).  Till date more than 
14 different S100 proteins between the molecular weight ranges (9-13kDa) are known. 
All S100 proteins share common structural motifs such as two EF-hands separated by 
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a hinge region and flanked by amino- and carboxy-terminal domains. The S100 
proteins play an important role in calcium sensing. Calcium is an important secondary 
messenger as it regulates keratinocyte proliferation and differentiation. The S100 
family of proteins are significantly involved in transduction of calcium signals for 
distinct cellular functions. S100 proteins regulate calcium homeostasis, calcium 
dependent phosphorylation, and organization of membranes and cytoskeletal 
filaments. The human S100 genes are organized within the epidermal differentiation 
complex on chromosome 1q21, suggesting a role in differentiation and proliferation of 
keratinocytes. It has been shown that, S100 proteins such as S100A7 (Psoriasin), 
S100A8 (MRP8, Calgranulin A), S100A9 (MRP14, Calgranulin B) and S100A12 
(Calgranulin C, EN-RAGE) are up-regulated in skin diseases which manifests itself as 
an abnormality in keratinocyte differentiation, hyperproliferation, and psoriasis 
(Benoit.S et al., 2006).   
 
5.1.4 S100A8 (M RP8, Calgranulin A) and S100A9 (M RP14, Calgranulin B) 
 
S100A8 and S100A9 are small (10 kDa and 13 kDa respectively) calcium 
binding proteins that form homo- and heterodimers and are mostly co-expressed. 
These proteins are usually expressed at low levels in the epidermis. The exact function 
of these proteins are still unknown, however there are a few studies that indicate the 
potential role of these proteins in wound repair, differentiation and stress response. 
The study that indicated the possible role of Calgranulin A and Calgranulin B in 
wound repair showed that the genes are differentially expressed in free electron laser 
or scalpel wounds created on mice (Nanjun et al., 2004). The mouse cDNA 
microarray study showed significant difference in expression levels of 89 of 15,000 
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genes. Calgranulin B was almost 30 times more highly expressed in scalpel wounds 
than in free-electron laser wounds. Northern blot analysis scalpel wounds expressed 
higher levels of Calgranulin A. This study suggested that these proteins may have a 
relevant therapeutic effect on wound repair.  The role of S100 A8 and S100 A9 in 
wound repair can be also attributed to the fact that they are differentially upregulated 
in differentiating suprabasal wound keratinocyte (Thorey et al.,2001) especially 12-24 
hours after injury. This study suggested that Calgranulin A and Calgranulin B are 
novel players in wound repair which may be involved in the cytoskeletal 
reorganization of wounded epidermis and also as a chemoattractant for inflammatory 
cells. These proteins are also strongly induced in human keratinocytes on exposure to 
UVB irradiation (Dazard et al., 2003).  
 
The proteome profile of tissues from regenerative MRL/MpJ-Faslpr mouse 
wounds detected high amounts of Calgranulin A and B. These mice were capable of 
regenerating full thickness ear wounds, than in non-regenerative C57BL/6J mice. A 
higher level of Calgranulin A and B was also shown to be associated with increased 
rate of wound repair. 
 
Studies done so far have indicated the role of Calgranulin A & B as novel players 
in wound repair based on genetic and proteomic profiling studies. But none of the 
studies done so far have tested the functional role of these proteins in vitro or in vivo 
and confirmed their roles in wound repair. The precise role of these proteins in 
epidermal wound repair can be concluded only by testing the respective proteins with 
respect to its wound healing property i.e. treating epidermal wounds with the proteins 
to check if the wound is healed in the presence of these proteins with respect to those 
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in the absence of the same. Thus this study aimed to study the role of Calgranulin A & 
B proteins in wound repair quantitatively and thus functionally establish the role of 
Calgranulin A & B as novel players of wound repair. 
 
5.1.5 Superoxide Dismutase-1 (SO D1) 
 
Superoxide dismutase is an anti-oxidant enzyme that catalyses the dismutation 
of superoxide anion (O2·±) to hydrogen peroxide (H2O2) according to the following 
half-reactions: 
  
M(n+1)+ í SOD + O2·± ĺ0n+ í SOD + O2 
Mn+ í SOD + O2·± + 2H+ ĺ0(n+1)+ í SOD + H2O2. 
where M = Cu (n=1) ; Mn (n=2) ; Fe (n=2) ; Ni (n=2). 
 
As mentioned previously, a skin injury initiates a series of reactions which 
includes inflammation, new tissue formation and matrix remodeling. During the early 
inflammation phase numerous polymorphonuclear leukocytes and macrophages are 
recruited at the site of the wound repair. On activation, they produce numerous 
reactive oxygen species (ROS) as a part of their defense strategy to eradicate the 
invading environmental pathogens.  Though ROS are beneficial for destroying the 
pathogens, increased levels of ROS may affect cell migration and proliferation and 
thus damage tissues and hence delayed wound repair. Studies have demonstrated 
strong mRNA expression of SOD1 after skin injury especially at hyperproliferative 




SOD1 has also been used to treat burn wounds in animals. Studies have shown 
that SOD1 treatment aided in the healing of scald wounds (Vorauer-Uhl et al., 2002). 
SOD1 was tested for  wound repair property by administrating the proteins in three 
different formulations² firstly injected directly into lesions, second an enzyme 
containing gel was prepared and applied topically and third the proteins was 
encapsulated into liposomes for topical application postburn. SOD1-treated animals 
exhibited increases rate of wound repair. The same study also marketed the liposomal-
encapsulated formulation of the protein as a potential lead for pharmaceuticals. These 
patented SOD1 trapped liposomes are currently being studied for improving the 
efficacy of SOD1 (Chiumiento et al., 2006). 
 
5.1.6 Calcium a key regulator in wound repair 
 
Calcium is a divalent metal cation that exists in the body in a variety of forms 
such as in the mineralized tissues of the bones and the teeth.  Some of the soft tissues 
also consist of small amounts of calcium. Calcium is known to extracellularly regulate 
and modulate intracellular cell proliferation and differentiation of mammalian 
epidermis. Wound healing cascade involves numerous metal ions like calcium, zinc, 
magnesium, copper, manganese, iron sodium and potassium. A balanced pool of these 
metal ions is required for the sequential wound healing cascade.  Studies have shown 
that there is a surge in calcium concentration from the early post wound phase 
continuing through the inflammation, proliferative and remodeling phases (Lansdown 
et al., 1999).  Studies have also shown that calcitonin injections that leads to elevated 
calcium levels in wounded rabbits and rats show improved healing.  Guinea pigs that 
were treated topically with calcium chloride showed significant increase in 
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granulation tissue formation (Lansdown et al., 1999). Thus it can be clearly seen that 
calcium plays an important role in cutaneous wound healing thus preventing it from 
becoming chronic. 
 
5.1.7 Objectives of this study 
 
An in depth literature study has indicated that some of the proteins identified in 
sweat may have wound healing properties. Hence it was decided to put this hypothesis 
to test by determining quantitatively if the some of the proteins in sweat could 
increase the rate of skin wound repair. For this, it was decided to first study this using 
an in vitro assay in which, a human non-tumorigenic immortalized keratinocyte cell 
line HaCaT was obtained.  The study design was, to grow the cells to confluence, 
followed by mechanically induced scratch wounds to mimic conditions of a wound or 
injury. The wounded cells were then treated with/without the test proteins and the rate 
at which the wound area healed/closed was determined quantitatively.  
 
Sweat is secreted onto the surface human skin; hence selection of an 
appropriate skin epithelial cell line was of pivotal importance for this study. HaCaT is 
a spontaneously transformed human epithelial cell line obtained from adult skin. The 
cell line is immortal but non-tumorigenic. HaCaT undergoes epidermal differentiation, 
like normal keratinocytes. HaCaT has been widely used for skin studies such as skin 
wound healing and effects of UV on skin (Boukamp et al., 1988) because it is a 
permanent human adult epithelial cell line with an inherent property of normal 
differentiation. Thus HaCaT was chosen as in vitro model for this study to 
quantitatively establish the wound healing property of human sweat proteins.  
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5.2 M ater ials and M ethods  
 
5.2.1  HaCaT cell culture  
 
The human immortalized non-tumorigenic keratinocyte cell line HaCaT was 
purchased from Cell Lines Service (CLS). The cells were maintained in Dulbecco 
0RGLILHG (DJOH¶V 0HGLXP '0(0 6LJPD VXSSOHPHQWHG ZLWK  YY IHWDO
bovine serum (FBS) (Hyclone), without antibiotics, in a humidified 5% CO2 
atmosphere at 37°C.   
 
5.2.2  Collection and concentration of sweat proteins. 
 
Healthy human sweat was collected using the method as described in sections 
2.2.1 and 2.2.2. 
 
5.2.3 Solublisation of lyophilized Sweat sample 
 
Previously lyophilized sweat sample were dissolved in 50mM Tris Buffer, pH 8.5. 
Complete solubilisation was achieved by vortexing the mixture followed by 
incubation for 1hr at 4°C with rotation. Insoluble substances were removed by 
centrifugation at 13000rpm for 1min. The solubilised sweat protein fraction thus 






5.2.4 In vitro wound repair assay using solubilised sweat/recombinant proteins  
 
Confluent monolayer of HaCaT cells were obtained by seeding them in a 24-
well plates. Spent media was removed and a single scratch wound was made in each 
well using a sterile disposable 1ml pipette tip. The cells were later washed thrice using 
sterile PBS to remove cellular debris. Then 40µl of varying concentration of 
solubilised sweat protein and 160µl of DMEM (+10% FBS) were added to the 
appropriate wells; PBS was added in the control wells. The cells were incubated at 
37°C/ 5% CO2 for 1 hour followed by the addition of 800µl of DMEM (+10% FBS) 
into each well to sustain growth of the cells. Photographs of the wounds were obtained 
at regular intervals -0, 8, 16, and 24 hours using a bright field microscope (Olympus 
CX41 Microscope, DP70 Digital Camera System), and the wound area was 
determined  using an image analysis software (PictZar 4.02MED, trial version, 
Medline Industries, Inc., Mudelein, IL). The percentage of area recovery was thus 
calculated as:  
 
Percentage Wound Closure = (Area of Wound at 0hr ± Area of Wound at x hr)   x 100 
Area of Wound at 0hr 
 
5.2.5 PC R amplification and expression of candidate sweat proteins 
 
The clones for Calgranulin A&B were purchased from Open Biosystems and 
the procedure to amplify and express the respective recombinant proteins was 





CalA_f:   ¶- AAT AAG GAT CCA TGT TGA CCG AGC TGG A -¶ 
 
CalA_r:   ¶- AAT AAG AAT TCC TAC TCT TTG TGG CTT TCT TCA TG - ¶ 
 
CalB_f:   ¶-AAT AAG GAT CCA TGA CTT GCA AAA TGT CGC AG -¶ 
 
CalB_r:   ¶±AAT AAC TCG AGT TAG GGG GTG CCC TCC C -¶ 
 
 
5.2.6 In vitro wound repair assay using recombinant proteins  
 
Confluent monolayer of HaCaT cells were grown in a 6-well plate. Spent 
media was removed and a single scratch was introduced in each well using the tip of a 
sterile disposable transfer pipette. PBS was added thrice to wash the wound bed from 
cellular debris.  200µl of varying concentration of filtered recombinant proteins and 
800µl of DMEM (+10% FBS) were added to the appropriate wells; PBS was added 
instead of recombinant proteins in the control wells. After 1 hour of incubation at 
37°C/ 5% CO2, 1ml of DMEM (+10% FBS) was added into each well. Photographs of 
the wounds were obtained at regular intervals -0, 8, 18, 24, and 30 hours using a bright 
field microscope (Olympus CX41 Microscope, DP70 Digital Camera System), and the 
wound area was determined  using an image analysis software (PictZar 4.02MED, 
trial version, Medline Industries, Inc., Mudelein, IL).. The percentage of area recovery 
was thus calculated as mentioned previously 
 
5.2.7 Inhibition of in vitro wound repai r by SO D1 using Diethylene T riamine 
Pentaacetic Acid (D TPA) 
 
Scratch wound assay was performed as mentioned previously. 100µl of filtered 
SOD1 (0.6mg/ml) and 900µl of DMEM (+10% FBS) was added to respective wells; 
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Control wells consisted of PBS instead of SOD1. The plate was then incubated at 
37°C/ 5% CO2 for an hour. After 1 hour  100µl of  filtered mixture of varying 
concentration (1mM, 10mM and 25mM) of Diethylene Triamine Pentaacetic Acid 
(DTPA) (Sigma) and 900µl of DMEM (+10% FBS) was added into the respective 
well.  Plain DMEM was added in the control wells instead of DTPA. The wound 
repair process was quantitatively assessed by obtaining digital photographs of the 
wounds using a bright field microscope (Olympus CX41 Microscope, DP70 Digital 
Camera System) at time 0, 8, and 24 hours. The areas of the wounds were calculated 
using PictZar 4.02MED (Medline Industries, Inc., Mudelein, IL).  
 
5.2.8 In Vivo wound excision study using Balb/c M ice. 
 
Six-week old female Balb/c mice were purchased from the Laboratory 
Animals Centre, National University of Singapore (NUS), Singapore. The wounding 
procedures carried out on the animals were in compliance with NUS Institutional 
Animal Care and Use Committee (IACUC). Isoflurane was used as an anesthetic at 
5% for induction and 3% for maintenance. The dorsal fur was removed using sterile 
scalpel blades. The shaved area was disinfected with three alternate cleansing with a 
germicidal scrub, and later rinsed with 70% ethanol. Two full-thickness wounds, was 
made using disposable sterile 5mm skin biopsy punches (Stiefel) one on each side of 
the midline, Digital photographs of the wounds were obtained at respective time 
intervals, which were later used for wound area analysis in PictZar 4.02MED (trial 
version, Medline Industries, Inc., Mudelein, IL). 50µl of Polyethylene-glycol 400 
(PEG) (Sigma-Aldrich) served as a vehicle control which was topically applied to the 
left wound of the midline of  each animal, the right wound was treated with 50 µl of 
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varying concentrations of the protein in PEG. Four concentrations (0.1mg/ml; 
0.2mg/ml; 0.4mg/ml; and 0.6mg/ml) of each protein were tested on five mice. The 
animals were placed in separate cages and the health of the mice was monitored by 
visual inspection and weighing every alternate day post-wounding. The protein/ PEG 
was topically applied once daily for five days, starting from the day of wounding. The 
wounds were photographed every alternate day (day 0, 2, 4 and 6). The wound areas 
were calculated using PictZar, and expressed as percentage wound areas. 
 
5.3 Results and Discussion 
 
5.3.1 In Vitro wound repai r assay using human eccrine sweat proteins. 
 
 
The presence of wound healing proteins in sweat was determined using 
lyophilized and solubilised sweat protein and confluent HaCaT cells. HaCaT cell 
distinctly showed that the scratch wounded HaCaT cells treated with solubilised sweat 
proteins healed at a rate faster than those that were treated just with the solubilising 
buffer (Fig 5.1). Also re-epithelization of wounded monolayer treated with sweat 
fraction was achieved by 24 hours as compared to the controls. The HaCaT scratch 
wound assay using solubilised sweat proteins clearly showed that human sweat 
consists of proteins that aid in wound healing of the skin in vitro. As the literature 
study pointed out the possible roles of Calgranulin A&B and SOD1 in wound repair, 
and since these proteins were also detected in the proteomic studies of human sweat 
(Table 2.1), it was decided to further test these proteins for their functional role in skin 







F ig 5.1 T reatment of mechanically scratch wounded HaCaT monolayer cells with solubilised sweat proteins accelerated  







F ig 5.2 Effect of solubilised sweat proteins on mechanically wounded HaCaT cells 











F ig 5.3 Effect of varying amounts of solubilised human sweat proteins on 
mechanically wounded HaCaT cells in vitro. 
 
5.3.2  cDN A amplification and expression of recombinant proteins 
The respective clones for Calgranulin A & B were purchased and the DNA 
was amplified, which was later used for transformation into a cloning vector followed 
by another transformation in an expression vector. This transformed expression vector 
was used to express and purify the recombinant proteins (Fig 5.4). 
 
F ig 5.4 Expression and purification of recombinant Cal A & B proteins  




5.3.3 In vitro wound healing assay using recombinant proteins 
 
 
While the hypothesis of this study was to test the functional role of Calgranulin 
A&B and SOD1 on wound repair, it was also decided to simultaneously test if any of 
the proteins that we expressed for the antimicrobial study have any functional role in 
wound healing. Hence each of the proteins that were expressed during the entire study 
was tested for their wound healing property including the commercially purchased 
protein Lactoferrin. 
 
The results obtained in Fig 5.5 clearly shows that of the proteins tested for 
wound healing property, the only proteins that distinctly increased rate of wound 
healing on treatment are Calgranulin B and SOD1. Treatment of mechanically 
wounded cells with proteins such as Calgranulin A, Cystatin A, Lactoferrin and 
Psoriasin showed no increase in the wound healing i.e. the rate at which the wounded 
healed was similar to the cells that were treated with PBS (Fig 5.6). 
 
From this study it can be concluded that the proteins Calgranulin B and SOD1 
that are present in human sweat have skin wound healing property. To further 
characterize these proteins with respect to skin wound repair it was decided to test 
these proteins at varying concentrations on mechanically wounded cells. This would 
help us establish if the proteins Calgranulin B and SOD1 show a dose dependent 







5.3.4 Calgranulin B- role in epidermal wound repair 
 
As mentioned previously cDNA microarray analysis studies have revealed that 
89 of the 15, 000 genes in mouse have significant difference in their expression levels. 
Of these Calgranulin A&B were almost 30 times more highly expressed in scalpel 
wounds (Nanjun et al., 2004). Northern Blot studies further confirmed the microarray 
studies, as it detected increased expression levels of Calgranulin A on day 2, 7 and 14 
from the day the wounds were created on test animals. Calgranulin B was also shown 
to have a higher level of expression in laser wounds. 
 
Hence it was hypothesized that probably these proteins are involved in wound 
healing and hence are highly expressed at the site of injury. Thus to put this 
hypothesis to test and functionally validate the role of Calgranulin A & B in epidermal 
wound repair, the respective recombinant proteins were expressed. For this functional 
study, scratch wounds were induced mechanically on the human keratinocyte cell line 
HaCaT monolayer to mimic conditions of a skin injury. Each of the scratch wounded 
monolayer was then treated with the test proteins. PBS treated scratch wounded 
monolayer served as controls. The rate of wound repair was monitored by capturing 
digital images at varying time periods and determining the percentage wound closure 
using the software. 
 
 In this study, both Calgranulin A&B were tested for their role in epidermal 
wound repair, but the results showed that only Calgranulin B was capable of wound 
repair (Fig 5.6). Once it was proved that Calgranulin B was involved in wound repair 







F ig 5.5 In vitro wound repair assay for candidate recombinant sweat proteins.  
Calgranulin B (Cal B), SOD1, Calgranulin A (Cal A), Cystatin A (Cys A), Lactoferrin 
(Lac) and Psoriasin (Pso). A: 8hr, B: 24hr, and C: 30hr. 
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faster than that of controls, it was decided to test if Calgranulin B shows a dose 
dependent wound repair response. 
 
As seen from Fig 5.9 Calgranulin B showed a dose dependent wound healing 
when tested DWYDU\LQJFRQFHQWUDWLRQVȝ0 ȝ0DQGȝ07RWKHEHVWRIRXU
knowledge, this study is the first to establish a functional role of Calgranulin B as 
novel player in epidermal wound healing in vitro. 
 
 
F ig 5.6  E ffect of recombiant proteins on the rate of wound closure of 














F ig 5.8 Effect of Calgranulin B on percentage wound closure of mechanically 
scratched HaCaT cells.  A : 8hr; B : 18hr; C : 24hr; D: 30hr. Monolayer cultures of 
HaCaT cells grown on a 6- well plate were scratched using a pipette tip, to introduce a 
wounded zone, followed by washing with PBS. The wounded cells were then treated 




F ig 5.9 Dose response curve for the effect of varying concentrations of 




5.3.5 Cu/Zn Superoxide Dismutase (SO D1) ± role in epidermal wound repai r. 
 
In an attempt to screen for proteins that aid in epidermal wound repair two 
proteins that are involved in wound repair were identified. One of them was 
Calgranulin B and the other protein that also showed to be involved in wound healing 
was SOD1. As seen from Fig 5.10 mechanically wounded HaCaT cells showed 
lampoidal crawling at a rate faster than those that were treated with PBS.  
  
 A dose response analysis showed that SOD1 increased the rate of migration of 
the mechanically wounded HaCaT cells in a dose dependent manner (Fig 5.12). The 
LQFUHDVHLQSHUFHQWDJHZRXQGFORVXUHZDVWHVWHGDWFRQFHQWUDWLRQVȝ0 ȝ0DQG
9.2 ȝ07KH results clearly showed that the percentage wound closure i.e. the rate at 
which the wound healed increased with increase in the concentration of the SOD1 
added to the wounded cells. 
 
5.3.6 Diethylene T riamine Pentaacetic Acid (D TPA)-an inhibitor of SO D1. 
 
 
To further validate the role of SOD1 in epidermal wound repair in vitro, the 
wounded cells were treated with SOD1 followed by the SOD1 inhibitor DTPA. This 
study was performed to test if the inhibition of SOD1 simultaneously inhibits the rate 
of wound healing of HaCaT cells. DTPA concentrations (0.1M, 1M, and 2.5M) were 




F ig 5.10 Effect of SO D1 on mechanically scratch wounded HaCaT cell monolayer. Monolayer cultures of HaCaT cells grown on a 6- well 





F ig 5.11 Effect of SO D1 on percentage wound closure of mechanically scratched 





F ig 5.12 Dose response curve for the effect of varying concent rations of SO D1 on 




Wounds were induced on to a confluent monolayer of HaCaT cells followed 
E\WUHDWPHQWZLWKȝ062'IROORwed by the addition of respective concentrations 
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of the inhibitor. The results showed that while the cells treated with SOD1 alone 
continued to heal faster over 24 hour time period, but the ones treated with SOD1 and 
DTPA showed decreased rate of wound healing Fig 5.13. It was observed that in the 
presence of DTPA the wound healing property of SOD1 was highly reduced as these 
wounds healed at a rate similar to that of those treated with PBS. This study clearly 





F ig 5.13 Dose dependent inhibition of SO D1 mediated wound repair in the 
presence of D TPA . A : 7hr and B : 24 hr. scratch wounded HaCaT cells were treated 






5.3.7 In vivo wound repair studies 
 
This study has proved so far that sweat proteins Calgranulin B and SOD1 have 
wound healing property in vitro. To further investigate whether these proteins 
continue to exhibit this property in vivo the proteins were tested using the animal 
model Balb/c mice. This information would prove useful as it would take us one step 
further in developing a drug that can be used topically for enhanced wound healing. 
The study was performed thrice with an interval of 20 days between each study. The 
results (Fig 5.14 and 5.16) showed that topical application of the proteins for 5 
consecutive days showed increased wound closure as compared to the animals that 
were treated with just PEG topically. 
 
For the in vivo wound healing studies four different concentrations of the 
proteins were used (0.1, 0.2, 0.4, 0.6mg/ml). Though four different concentrations 
were tested no dose response was observed (Fig 5.15 and 5.17).  
 
 The wound repair studies using the sweat proteins Calgranulin B and SOD1 
showed that these two proteins not only increased the rate of wound closure of 
mechanically wounded HaCaT cells in vitro but also showed that topical application 
of these proteins for 5 consecutive days aided in the healing of punch wounds made on 






 F ig 5.14 In vivo wound repai r studies to test the wound repai r property of Calgranulin B using Balb/c mice as an animal model. 6 ±
weeks old Balb/c mice received 5mm punch wounds on their dorsal area. Daily application of Calgranulin B for five consecutive days enhanced 














F ig 5.16 In vivo wound repair studies to test the wound healing property of SO D1 using Balb/c mice as an animal model. 6 ±weeks old 










Wound repair is a complex process involving clotting, inflammation, 
granulation and tissue remodeling. The process of wound healing involves interaction 
of different cells, extracellular matrix proteins and their receptors.  
 
Delayed wound healing can cause significant morbidity in patients and may 
lead to complications such as wound dehiscence and anastamotic breakdown and 
chronic non healing ulcers. The cost of treating such complications may be extreme as 
it may require prolonged hospitalization and also altered life styles.  Today much of 
the efforts are being focused on the identification of drugs for rapid and cost effective 
treatments. This includes the identification of novel wound repair mediators followed 
by the identification of different pathways by which these mediators accelerate the 
rate of wound repair. 
 
This study began by observing that sweat proteins aided in the wound closure 
of the mechanically scratched keratinocyte cell line HaCaT. Followed by which, 
recombinant proteins Cystatin A, Psoriasin, Lactoferrin, Calgranulin A & B and 
SOD1 that were previously identified to be present in healthy human sweat were 
expressed and purified.  The objective was to test if these proteins were involved in 
epidermal wound healing. By means of an in vitro model for wound healing system 
that involved the epidermal keratinocyte HaCaT and mechanically induced scratch 
wounds, the wound healing property of the proteins were tested. It was observed that 
Calgranulin B and SOD1 significantly improved the rate of wound closure/repair as 
compared to the other proteins as well as the controls. On establishing the role of 
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Calgranulin B and SOD1 in skin wound repair, the role of these proteins were further 
validated by performing a dose response study. The results clearly showed that both 
Calgranulin B and SOD1 enhanced the rate of wound repair in a dose dependant 
manner in vitro. 
 
While the proteins Calgranulin A and Calgranulin B improved the wound 
closure in vitro, it was also vital for this study, to show that these proteins exhibit the 
same properties in vivo.  Hence the animal model Balb/c mice were chosen for in vivo 
studies. On testing these proteins for wound healing on punch wounds made on the 
back of the Balb/c mice it was observed that the wounds treated with the respective 
proteins healed faster than those that were treated just with vehicle controls. Hence 
proving that Calgranulin B and SOD1 both have a role in keratinocyte wound repair 
when tested in vitro and in vivo. 
 
As mentioned previously, the process of wound repair involves a cascade of 
pathways, growth factors and metal cations such as Ca, Zn etc. Interestingly 
Calgranulin B belongs to the S100 family of proteins that are also known to be 
calcium binding proteins. Calcium is known to be one of the key regulators in wound 
healing pathway. Hence it is suggested that probably Calgranulin B aids in the 
accumulation/ trafficking of calcium at the site of wound bed which ultimately leads 
to enhanced wound healing and repair. 
 
Apart from focusing on the mechanism of action of these proteins in wound 
repair, future studies also needs to focus on the growth factor signals that are involved 
in the wound healing process. Experiments focusing on the effect of Calgranulin B 
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and SOD1 on these growth factor signals can help decipher the pathway for epidermal 
wound repair in the presence of Calgranulin B and SOD1. Immunohistochemistry 
studies, molecular imaging and quantitative measurements for these growth factors 
will shed light on the mechanism by which these proteins accelerate wound healing 
and repair 
 
Selection of a drug for treatment of wounds is an important decision that a 
surgeon or medical practitioner has to make. Most healing failures occur in patients 
with diabetes, infection, immuno-suppression, malnutrition and obesity. Mostly the 
drug of choice is the ones that are routinely used. But the pursuit for new drugs for 
rapid and cost effective treatment is still on. The most preferred drug of choice is the 
naturally occurring growth factors or pharmacological agents such as proteins that 
mediate wound repair in normal healthy individuals. This study has lead to the 
identification of two proteins Calgranulin B and SOD1 that are naturally produced by 
humans and deposited onto the skin by sweat. These proteins enhanced the rate of skin 
wound repair when tested on mechanically scratched human keratinocyte cell line 
HaCaT, as well as on animal model- Balb/c mice. Both the proteins proved to 
accelerate wound repair efficiently, suggesting their thriving role as future drugs for 















C H APT E R 6: SI G NIF I C A N C E A ND F U T UR E L E A DS 
 
 
  This thesis has successfully achieved the following aims: 1) Identify the major 
proteins components of healthy human sweat using two of the most widely established 
and complimentary tools in the proteomic study of human body fluids.. 2) Establish 
the role of sweat proteins as an important part of the innate immune defense. This was 
achieved by identification of a few sweat proteins with anti-bacterial, anti-viral and 
epidermal wound repair function. 
 
The use of 2D-MALDI-TOF/TOF MS and 2D-LC-MS/MS lead to the 
identification of 98 unique proteins in sweat. These identified proteins not only 
included those that were reported previously in literature but also many that were not 
known to be present in human sweat. To the best of our knowledge, this study is the 
first to identify the entire repertoire of proteins present in healthy human sweat. While 
sweat test has been known to be used for the diagnosis of Cystic fibrosis, the proteins 
present in sweat could serve as biomarkers for skin diseases. The non-invasive method 
of collection of sweat, and simple equipment for transfer and storage makes it an ideal 
body fluid for diagnostic, prognostic and treatment follow up markers.  
 
The identification of 98 proteins in human sweat opened several avenues to 
probe the functions of these proteins. Previous studies have established that few of the 
sweat proteins have an antimicrobial role, hence this study set off to identify the 
presence of  other proteins with the same function and also reveal the presence of 
proteins in sweat with other immune function roles making the sweat proteins an 
eminent part of the innate immune defense system. This quest lead to the 
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identification of three novel antimicrobial sweat proteins- SOD1, Cystatin A and 
lactoferrin. While Cystatin A has an antibacterial effect on E .coli, similar to that of the 
previously reported protein Psoriasin, SOD1 and lactoferrin exhibit antibacterial 
activity against S.pyogenes and S.epidermidis respectively. Both these pathogens can 
cause superficial to lethal infections, leading to fatal consequences. The antibacterial 
function of Cystatin A, SOD1 and lactoferrin, makes it an ideal candidate for the 
replacement of antibiotics that are currently used in the treatment of infections caused 
by respective bacteria. Though this study has established the functional role of 
Cystatin A, SOD1 and Lactoferrin as antimicrobial proteins the exact mechanism of 
action by which these proteins exert their antibacterial effect still remains to be 
deciphered.  While this study has established the antibacterial role of these proteins 
and also their functional stability at sweat pH and salt concentrations in vitro, in vivo 
studies using animal models would further signify the antibacterial function of these 
sweat proteins. Such studies will bridge the gap between the in vitro characterization 
and the clinical evaluation of these antibacterial proteins.  
 
Viruses such as HSV-1 are one of the most common communicable diseases. 
HSV-1 usually causes infections in the face, skin and trunk. Over one third of the 
world populations suffers from HSV infections several times a year hence the 
treatment of HSV-1 represents an important goal as no vaccines are available. Sweat 
is deposited on to the skin and thus is the proteins present in sweat. The sweat proteins 
were analyzed for their antiviral function against HSV-1 and it was observed that 
Cystatin A and Lactoferrin had antiviral activity. It was also demonstrated that these 
proteins inhibit important stages of the HSV-1 replication cycle, further emphasizing 
their potential application in antiviral therapy.  For potential use of these proteins in 
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antiviral therapy, further tests using animal models should be done. The results of in 
vivo testing will provide further evidence on the efficacy and also the bioavailability 
of Cystatin A and Lactoferrin as choice of treatment for HSV-1 infections. 
 
The most important and vital function of human skin is to prevent foreign 
particles and pathogens from entering into the body. This is done by maintaining an 
intact nature of the skin free of breaks. But occasionally human skin is prone to 
scratches and wounds causing a breach in the intact nature of the skin. These wounds 
on the skin should heal to restore the preventive functions of skin and thus avert lethal 
consequences. Numerous growth factors and proteins aid in the re-epithelization of 
skin wounds. In this study, the sweat proteins Calgranulin B and SOD1 have been 
shown to possess epidermal wound repair function using both in vitro and in vivo 
models.  Literature studies provided the clues for the probable role of Calgranulin B 
by genetic and proteome profile studies and that of SOD1 on burn wounds. This study, 
to the best of our knowledge, is the first to provide quantitative evidence for the skin 
wound repair function of Calgranulin B and SOD1. It is suggested that SOD1 
mediates wound repair by quenching the reactive oxygen species (ROS) generated 
during infection of wounded site, as ROS can inhibit keratinocyte proliferation. The 
exact mechanism of action of Calgranulin B as a wound repair mediator still needs to 
be determined. Calgranulin B being a member of the S100 family of proteins which 
are generally calcium binding proteins, it is hypothesized that Calgranulin B 
accelerates wound repair by increasing the availability of Calcium at the wound bed. It 
is widely accepted that numerous cytokines are set to play during the process of 
wound repair. Immunohistochemistry studies to identify the cytokines released during 
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the process of wound repair in presence of Calgranulin B and SOD1will act as 
auxiliary information in describing the pathway for wound repair. 
 
This study has evaluated the functions of few of the sweat proteins identified ± 
Cystatin A, SOD1, Lactoferrin, and Calgranulin B. But our proteome profile of human 
sweat shows that there are numerous other proteins whose functions still are unknown. 
To name a few, zinc- alpha-2-glycoprotein (ZAG), Prolactin-inducible-protein (PIP), 
Serpin family of proteins, Clusterin, Cathepsins, Caspases etc. It will be interesting to 
comprehend the roles of these proteins in sweat. Of particular interest is the protein 
ZAG, this protein is one of the most abundant protein present in sweat. ZAG is also 
present in other body fluids. This protein has been suggested to have functional roles 
in fertilization, lipid mobilization and most interestingly a probable immune function 
role due to its structural similarity to MHC-1 molecule. But still this protein is labeled 
as a protein with unknown function. The protein PIP has been shown to be expressed 
in breast cancers, but its physiological role is still poorly understood. It will be 
interesting to study the role of PIP in sweat.  In short, numerous proteins were 
identified to be present in sweat in this study; the functional roles of the same in sweat 
of many are still unknown.  
 
In conclusion, this study has presented initial efforts in unraveling the long 
standing mystery about the composition of healthy human sweat and functions of the 
sweat proteins. This study has opened ample opportunities for further studies into the 
functional role of these proteins and the use of the same for therapeutic purposes.  
This study has no doubt established the fact that while skin forms a physical barrier, 
sweat forms a superficial barrier against the environmental pathogens. This study thus 
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provides substantial evidence to prove that sweat proteins form an important part of 
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